,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,421,1,3,,17389531,441074,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
1,426,1,2,,17389531,441074,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
2,427,1,1,,17389531,441074,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
3,433,1,1,,17389531,441074,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
4,434,1,2,,17389531,441074,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
5,435,1,2,,17389531,441074,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
6,445,3,1,,17389531,441074,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
7,530,1,1,,17389531,441074,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
8,540,1,1,,17389531,441074,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
9,541,1,1,,17389531,441074,Inconclusive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
10,542,1,1,,17389531,441074,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
11,543,1,1,,17389531,441074,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
12,544,2,1,,17389531,441074,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
13,545,1,1,,17389531,441074,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
14,546,1,1,,17389531,441074,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
15,584,1,3,,17389531,441074,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
16,585,1,4,,17389531,441074,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
17,595,1,3,,17389531,441074,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
18,596,1,2,,17389531,441074,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
19,603,1,2,,17389531,441074,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
20,605,1,2,,17389531,441074,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
21,608,1,6,,11537615,441074,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
22,654,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
23,655,1,1,,17389531,441074,Inconclusive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
24,656,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
25,657,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
26,658,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
27,659,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
28,660,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
29,661,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
30,662,1,1,,17389531,441074,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
31,663,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
32,664,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
33,665,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
34,666,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
35,667,1,1,,17389531,441074,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
36,875,1,2,,17389531,441074,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
37,880,2,1,,17389531,441074,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
38,880,2,1,,17389531,441074,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
39,881,2,2,,17389531,441074,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
40,884,1,2,,17389531,441074,Inconclusive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
41,885,1,2,,17389531,441074,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
42,886,1,2,,17389531,441074,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
43,886,1,2,,17389531,441074,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
44,887,1,2,,17389531,441074,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
45,889,1,3,,17389531,441074,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
46,892,1,2,,17389531,441074,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
47,893,1,2,,17389531,441074,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
48,893,1,2,,17389531,441074,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
49,894,2,1,,17389531,441074,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
50,900,1,3,,17389531,441074,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
51,902,1,2,,17389531,441074,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
52,912,1,2,,17389531,441074,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
53,921,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
54,923,1,2,,17389531,441074,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
55,924,1,2,,17389531,441074,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
56,925,1,2,,17389531,441074,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
57,926,1,2,,17389531,441074,Inconclusive,38016895.0,7253.0,25.1189,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
58,938,1,2,,17389531,441074,Inconclusive,38016895.0,7253.0,25.1189,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
59,946,1,2,,17389531,441074,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
60,947,1,2,,17389531,441074,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
61,948,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
62,955,1,2,,17389531,441074,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
63,960,1,2,,17389531,441074,Inconclusive,,,12.5893,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
64,961,1,2,,17389531,441074,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
65,962,1,2,,17389531,441074,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
66,963,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
67,964,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
68,965,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
69,966,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
70,967,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
71,968,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
72,969,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
73,970,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
74,971,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
75,972,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
76,973,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
77,974,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
78,975,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
79,976,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
80,977,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
81,978,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
82,979,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
83,980,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
84,981,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
85,982,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
86,983,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
87,984,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
88,985,1,2,,17389531,441074,Inconclusive,,,63.0957,Potency,Cell Viability - LYMP2-018,Confirmatory,,
89,986,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
90,987,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
91,988,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
92,989,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
93,993,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
94,994,1,2,,17389531,441074,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
95,995,1,2,,17389531,441074,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
96,1030,2,1,,17389531,441074,Inconclusive,30582681.0,216.0,12.5893,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
97,1033,2,2,,11537615,441074,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
98,1195,1,2,,48416508,441074,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
99,1332,1,1,,49699334,441074,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
100,1452,1,1,,17389531,441074,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
101,1457,1,1,,17389531,441074,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
102,1458,1,1,,17389531,441074,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
103,1469,1,1,,17389531,441074,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
104,1471,2,1,,17389531,441074,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
105,1476,2,1,,17389531,441074,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
106,1477,1,1,,17389531,441074,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
107,1478,2,1,,17389531,441074,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
108,1479,1,2,,17389531,441074,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
109,1511,1,3,,56320931,441074,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
110,1549,1,2,,11537615,441074,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
111,1552,1,3,,11537615,441074,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
112,1554,1,1,,56320931,441074,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
113,1637,1,2,,11537615,441074,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
114,1648,1,2,,11537615,441074,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
115,1662,1,2,,56320931,441074,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
116,1663,1,2,,56320931,441074,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
117,1672,1,3,,56320931,441074,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
118,1813,1,2,,56320931,441074,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
119,1814,1,2,,56320931,441074,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
120,1832,2,1,,56320931,441074,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
121,1850,2,1,,56320931,441074,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
122,1863,2,1,,56320931,441074,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
123,1875,2,1,,56320931,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
124,1885,2,1,,56320931,441074,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
125,1899,1,3,,56320931,441074,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
126,1903,2,3,,56320931,441074,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
127,1906,1,3,,56320931,441074,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
128,1910,1,2,,56320931,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
129,1947,1,2,,56320931,441074,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
130,1948,1,1,,17389531,441074,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
131,1950,1,3,,56320931,441074,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
132,1962,1,2,,56320931,441074,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
133,1974,1,2,,56320931,441074,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
134,1979,1,1,,56320931,441074,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
135,1987,1,2,,56320931,441074,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
136,1996,2,2,,56320931,441074,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
137,2016,1,3,,56320931,441074,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
138,2023,1,3,,56320931,441074,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
139,2025,1,3,,56320931,441074,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
140,2029,1,3,,56320931,441074,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
141,2052,2,1,,56320931,441074,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
142,2057,1,2,,56320931,441074,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
143,2066,1,4,,56320931,441074,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
144,2094,1,2,,56320931,441074,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
145,2094,1,2,,56320931,441074,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
146,2094,1,2,,56320931,441074,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
147,2097,1,2,,56320931,441074,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
148,2098,1,1,,56320931,441074,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
149,2099,1,1,,56320931,441074,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
150,2101,1,1,,17389531,441074,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
151,2101,1,1,,56320931,441074,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
152,2107,1,1,,17389531,441074,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
153,2112,1,1,,17389531,441074,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
154,2120,1,1,,17389531,441074,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
155,2129,1,2,,56320931,441074,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
156,2130,1,3,,56320931,441074,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
157,2156,2,2,,56320931,441074,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
158,2174,1,3,,56320931,441074,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
159,2177,1,3,,56320931,441074,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
160,2216,1,3,,56320931,441074,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
161,2221,1,2,,56320931,441074,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
162,2227,1,2,,56320931,441074,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
163,2234,1,2,,56320931,441074,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
164,2235,1,2,,56320931,441074,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
165,2237,1,2,,56320931,441074,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
166,2239,1,2,,56320931,441074,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
167,2240,1,1,,85788831,441074,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
168,2241,1,1,,85788831,441074,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
169,2247,1,2,,56320931,441074,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
170,2275,1,1,,85788831,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
171,2280,2,3,,56320931,441074,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
172,2297,1,2,,85860348,441074,Unspecified,,,,,Inhibition Frequency Index,Other,,
173,2300,1,3,,56320931,441074,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
174,2302,1,2,,85860348,441074,Active,111034851.0,,,,Inhibition of P. falciparum Dd2,Screening,,
175,2303,1,2,,85860348,441074,Inactive,,,,,Inhibition of HepG2 cell line,Screening,,
176,2304,1,2,,85860348,441074,Inactive,111034851.0,,,,Inhibition of P. falciparum LDH,Screening,,
177,2305,1,2,,85860348,441074,Unspecified,,,0.12,XC50_3D7,XC50 for P. falciparum 3D7,Confirmatory,,
178,2306,1,2,,85860348,441074,Active,124513266.0,814112.0,,,Inhibition of P. falciparum 3D7,Screening,,
179,2313,1,1,,85788831,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
180,2322,1,1,,85788831,441074,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
181,2330,1,1,,85788831,441074,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
182,2391,1,1,,56320931,441074,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
183,2435,1,2,,56320931,441074,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
184,2445,1,2,,56320931,441074,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
185,2462,1,1,,56320931,441074,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
186,2462,1,1,,56320931,441074,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
187,2517,2,1,,17389531,441074,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
188,2517,2,1,,56320931,441074,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
189,2546,1,1,,17389531,441074,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
190,2549,1,1,,17389531,441074,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
191,2550,1,3,,56320931,441074,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
192,2551,1,1,,17389531,441074,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
193,2553,1,2,,56320931,441074,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
194,2557,1,3,,56320931,441074,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
195,2563,1,1,,56320931,441074,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
196,2606,1,2,,56320931,441074,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
197,2629,1,1,,56320931,441074,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
198,2642,1,2,,56320931,441074,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
199,2648,1,2,,56320931,441074,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
200,2650,2,1,,56320931,441074,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
201,2661,1,1,,56320931,441074,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
202,2676,1,2,,56320931,441074,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
203,2685,1,1,,56320931,441074,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
204,2690,1,2,,56320931,441074,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
205,2716,1,1,,56320931,441074,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
206,2717,1,2,,56320931,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
207,2718,1,1,,56320931,441074,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
208,2751,2,2,,56320931,441074,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
209,2796,1,4,,56320931,441074,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
210,2797,1,2,,56320931,441074,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
211,7783,3,4,,103401109,441074,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
212,8002,5,2,,103401109,441074,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
213,19424,3,4,,103401109,441074,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
214,19468,3,3,,103401109,441074,Unspecified,,,,,Partition coefficient (logP),Other,12699389.0,
215,22280,3,3,,103401109,441074,Unspecified,,,,,Percent change from control value for Vmax at 0.1 uM of the compound.,Other,2299628.0,
216,22283,4,3,,103401109,441074,Unspecified,,,,,Percent change from control value for Vmax at 10 uM of the compound.,Other,2299628.0,
217,22285,3,3,,103401109,441074,Unspecified,,,,,Percent change from control value for Vmax at 1 uM of the compound.,Other,2299628.0,
218,22287,3,3,,103401109,441074,Unspecified,,,,,Percent change from control value for Vmax at 30 uM of the compound.,Other,2299628.0,
219,23954,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
220,23957,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
221,23959,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
222,23960,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
223,23961,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
224,23963,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
225,23965,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
226,23970,4,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
227,23971,3,3,,103401109,441074,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
228,23973,4,3,,103401109,441074,Unspecified,,,,,"Partition coefficient (logD, measured by HPLC, log k')",Other,6167716.0,
229,26296,4,4,,103401109,441074,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
230,26362,4,3,,103401109,441074,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
231,27167,3,4,,103401109,441074,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
232,28233,3,3,,103401109,441074,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
233,28235,3,3,,103401109,441074,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
234,28236,3,3,,103401109,441074,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
235,28681,3,4,,103401109,441074,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
236,29139,4,3,,103401109,441074,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
237,29140,4,3,,103401109,441074,Unspecified,,,,,Apparent value (pKa) calculated with ACD/pKa (experimental pKa value),Other,12477351.0,
238,29337,3,3,,103401109,441074,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
239,29359,3,3,,103401109,441074,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
240,29423,3,4,,103401109,441074,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
241,29813,3,3,,103401109,441074,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
242,29925,5,2,,103401109,441074,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
243,54410,6,5,,103401109,441074,Active,,,32.0,Ki,Binding affinity towards cytochrome P450 2C9,Confirmatory,14761192.0,
244,54562,6,7,,103401109,441074,Active,117241.0,266684.0,19.9,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D1 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
245,54564,6,7,,103401109,441074,Active,117242.0,25053.0,2.8,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D2 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
246,54565,6,7,,103401109,441074,Active,3915646.0,24303.0,26.9,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D3 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
247,54566,6,7,,103401109,441074,Active,117244.0,,47.2,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D4 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
248,54570,6,7,,103401109,441074,Active,84028191.0,1565.0,0.0033,IC50,Inhibition of MAMC O-dealkylation mediated by human Cytochrome P450 2D6 expressed in human lymphoblastoid cell line,Confirmatory,12502361.0,
249,54923,6,5,,103401109,441074,Unspecified,,,50.0,IC50,Inhibition of human cytochrome P450 3A4,Confirmatory,12699389.0,
250,55930,3,3,,103401109,441074,Unspecified,,,,,Conduction time was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
251,55938,3,3,,103401109,441074,Unspecified,,,,,Conduction time was determined by intraduodenal administration of two dosages of 30 mg/kg (high dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
252,56065,3,3,,103401109,441074,Unspecified,,,,,Conduction time was determined by intraduodenal administration of two dosages of 30 mg/kg (high dose)of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
253,56077,3,3,,103401109,441074,Unspecified,,,,,Conduction time was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
254,56512,3,4,,103401109,441074,Unspecified,,,,,Activity duration index was evaluated in mixed-breed or Beagle dogs after intravenous administration.,Other,7420355.0,
255,57000,3,5,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity was evaluated in mixed-breed or Beagle dogs after intravenous administration.,Other,7420355.0,
256,57161,3,4,,103401109,441074,Unspecified,,,,,Antiarrhythmic potential in conscious dogs; value ranges from +50 to +60,Other,6827566.0,
257,58473,3,3,,103401109,441074,Unspecified,,,,,Heart rate was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
258,58474,3,3,,103401109,441074,Unspecified,,,,,Heart rate was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
259,58485,3,3,,103401109,441074,Unspecified,,,,,Heart rate was determined by intraduodenal administration of two dosages of 30 mg/kg (high dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
260,58486,3,3,,103401109,441074,Unspecified,,,,,Heart rate was determined by intraduodenal administration of two dosages of 30 mg/kg (high dose)of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
261,58609,3,3,,103401109,441074,Unspecified,,,,,Evaluated for ouabain-induced arrhythmia in anesthetized adult male mongrel dogs. Administered intravenously.,Other,6384519.0,
262,58612,3,3,,103401109,441074,Unspecified,,,,,Concentration required to reverse ouabain induced arrhythmia in dogs,Other,7359531.0,
263,58699,3,3,,103401109,441074,Unspecified,,,,,Left ventricular refractory period was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
264,58700,3,3,,103401109,441074,Unspecified,,,,,Left ventricular refractory period was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
265,58701,3,3,,103401109,441074,Unspecified,,,,,Left ventricular refractory period was determined by intraduodenal administration of two dosages of 30 mg/kg (high dose)of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
266,58702,3,3,,103401109,441074,Unspecified,,,,,Left ventricular refractory period was determined by intraduodenal administration of two dosages(high dose) of 30 mg/kg of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
267,58748,3,3,,103401109,441074,Unspecified,,,,,Compound was evaluated for maximum reduction of ectopic beats after oral administration at a dose 25 mg/kg to dog.,Other,7420355.0,
268,58769,3,3,,103401109,441074,Unspecified,,,,,Compound was evaluated for duration of action after oral administration at a dose 25 mg/kg to dog.,Other,7420355.0,
269,58775,4,4,,103401109,441074,Unspecified,,,,,Duration for the antiarrhythmic activity was measured,Other,7205883.0,
270,58776,3,3,,103401109,441074,Unspecified,,,,,Duration for the sinus rhythm recovery was measured,Other,7205883.0,
271,58778,4,3,,103401109,441074,Unspecified,,,,,Duration of ischemic arrhythmias in dogs determined in minutes.,Other,6147415.0,
272,58964,3,3,,103401109,441074,Unspecified,,,,,Duration of the reversal of ouabain induced arrhythmia was measured,Other,7359531.0,
273,59158,3,3,,103401109,441074,Unspecified,,,,,Heart rate of the dog was measured after drug administration to dogs,Other,7359531.0,
274,59159,3,3,,103401109,441074,Unspecified,,,,,Heart rate of the dog was measured after ouabain administration to dogs,Other,7359531.0,
275,59318,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against epinephrine induced ventricular fibrillation ) in post infarcted conscious dog administered iv(ear or caudal vein),Other,3572966.0,
276,59322,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic efficacy in vivo against Harris model,Other,2299628.0,
277,59323,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic efficacy in vivo against PES model,Other,2299628.0,
278,59395,4,3,,103401109,441074,Unspecified,,,,,Minimal effective dose that resulted in significant reduction in PVC frequency in conscious dogs by po administration after 24 hours of coronary artery ligation,Other,8230126.0,
279,59401,3,4,,103401109,441074,Unspecified,,,,,Minimum effective dose evaluated in mixed-breed or Beagle dogs after intravenous administration,Other,7420355.0,
280,59510,3,3,,103401109,441074,Unspecified,,,,,Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 10 mg/kg iv,Other,7205883.0,
281,59531,3,3,,103401109,441074,Unspecified,,,,,"Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose mg/kg, iv=12.5",Other,7205883.0,
282,59532,3,3,,103401109,441074,Unspecified,,,,,"Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose mg/kg, iv=25",Other,7205883.0,
283,59749,3,4,,103401109,441074,Unspecified,,,,,Mean arterial blood pressure was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
284,59750,3,4,,103401109,441074,Unspecified,,,,,Mean arterial blood pressure was determined by intraduodenal administration of two dosages of 10 mg/kg (low dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
285,59751,3,4,,103401109,441074,Unspecified,,,,,Mean arterial blood pressure was determined by intraduodenal administration of two dosages of 30 mg/kg (high dose)of compound in anesthetized dogs. Value was reported for experiment 1,Other,3681896.0,
286,59752,3,4,,103401109,441074,Unspecified,,,,,Mean arterial blood pressure was determined by intraduodenal administration of two dosages of 30 mg/kg(high dose) of compound in anesthetized dogs. Value was reported for experiment 2,Other,3681896.0,
287,60110,3,3,,103401109,441074,Unspecified,,,,,Number of dogs reverted ouabain induced arrhythmia,Other,7359531.0,
288,60112,3,3,,103401109,441074,Unspecified,,,,,Number of dogs used ouabain induced arrhythmia,Other,7359531.0,
289,60169,6,3,,103401109,441074,Unspecified,,,,,The compound was tested for antiarrhythmic activity in infarcted conscious dog through iv(ear or caudal vein),Other,3572966.0,
290,60406,3,3,,103401109,441074,Unspecified,,,,,Compound was evaluated for onset of action after oral administration at a dose 25 mg/kg to dog.,Other,7420355.0,
291,60426,3,3,,103401109,441074,Unspecified,,,,,Concentration of ouabain required to induce arrhythmia in dogs,Other,7359531.0,
292,60842,3,3,,103401109,441074,Unspecified,,,,,Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 10 mg/kg iv,Other,7205883.0,
293,60858,4,3,,103401109,441074,Unspecified,,,,,"Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose mg/kg, iv",Other,7205883.0,
294,61881,3,3,,103401109,441074,Unspecified,,,,,Activity against ouabain-induced ventricular arrhythmia was measured as percent of sinus rhythm recovery at dose of 10 mg/kg iv,Other,7205883.0,
295,61925,4,4,,103401109,441074,Unspecified,,,,,Effective dose administered intravenously to elicit Antiarrhythmic efficacy in anesthetized dogs was reported; Number of animals effective at that dose is 1.,Other,3681896.0,
296,61926,4,4,,103401109,441074,Unspecified,,,,,Effective dose administered intravenously to elicit Antiarrhythmic efficacy in anesthetized dogs was reported; Number of animals effective at that dose is 2.,Other,3681896.0,
297,62986,3,3,,103401109,441074,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs, by glass bead method. 60 mg/kg was administered perorally and percent sinus beats after compound administration, was reported.",Other,6147415.0,
298,62987,3,3,,103401109,441074,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs, by glass bead method. 60 mg/kg was administered perorally and percent sinus beats before compound administration, was reported.",Other,6147415.0,
299,62988,3,3,,103401109,441074,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs. 10 mg/kg was injected intravenously and percent sinus beats after compound administration, was reported.",Other,6147415.0,
300,62989,3,3,,103401109,441074,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs. 10 mg/kg was injected intravenously and percent sinus beats before compound administration, was reported.",Other,6147415.0,
301,74038,4,3,,103401109,441074,Unspecified,,,,,Effective dose in vivo for cardiac refractoriness (ERP) using paced guinea pig model,Other,8230126.0,
302,74456,3,3,,103401109,441074,Unspecified,,,,,Local anesthetic activity using modification of the guinea pig intracutaneous wheal method.,Other,7359531.0,
303,74895,3,3,,103401109,441074,Unspecified,,,,,Amount of ouabain needed for production of ventricular arrhythmias that causes death in guinea pig by cardiac arrest at a dose of 2 mg/kg iv given 5 min prior,Other,3806567.0,
304,74898,3,3,,103401109,441074,Unspecified,,,,,Amount of ouabain needed for production of ventricular extra-systoles at a dose of 2 mg/kg (iv given 5 min prior) in guinea pig,Other,3806567.0,
305,74901,3,3,,103401109,441074,Unspecified,,,,,Amount of ouabain needed for production of ventricular fibrillation at a dose of 2 mg/kg (iv given 5 min prior) in guinea pig,Other,3806567.0,
306,75366,3,3,,103401109,441074,Unspecified,,,,,Percent change in the mean time to first Ouabain-induced arrhythmia was determined in Guinea pig at 10 mg/kg dose,Other,2299628.0,
307,75522,3,3,,103401109,441074,Unspecified,,,,,Maximal follow rate showing the contractile frequencies of atria to electrical stimulation 10 min after incubation with right atria of guinea pig.,Other,6147415.0,
308,76705,3,4,,103401109,441074,Unspecified,,,,,Parasympatholytic activity and the % inhibition of guinea pig ileum contractile force at 4 mg/L of base was reported.,Other,3973901.0,
309,76706,3,4,,103401109,441074,Unspecified,,,,,Parasympatholytic activity was assessed from the ability to inhibit electrically stimulated contraction of isolated guinea pig ileum at 4 mg/L of base,Other,6384519.0,
310,77947,4,3,,103401109,441074,Unspecified,,,,,Minimal effective dose that resulted in significant delay in the onset of arrhythmias in guinea pig with iv administration of aconitine hydrochloride,Other,8230126.0,
311,78122,4,3,,103401109,441074,Unspecified,,,,,In vivo index of cardiac contractility using paced guinea pig model,Other,8230126.0,
312,79337,5,3,,103401109,441074,Active,,,1.0,Kd,Anticholinergic activity is assessed in guinea pig ileum at 10 uM,Confirmatory,6384519.0,
313,80741,5,1,,103401109,441074,Unspecified,,,,,Evaluated for decrease in contractility in isolated guinea pig atria,Other,7452671.0,
314,80742,5,1,,103401109,441074,Unspecified,,,,,Evaluated for decrease in maximal driving frequency in isolated guinea pig atria,Other,7452671.0,
315,80743,5,1,,103401109,441074,Unspecified,,,,,Evaluated for decrease in spontaneous frequency of atrial rate in isolated guinea pig atria,Other,7452671.0,
316,91481,4,7,,103401109,441074,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
317,125784,6,7,,103401109,441074,Active,84028191.0,1565.0,0.04,Ki,Inhibition of 1'-hydroxybufuralol formation by human liver microsomes,Confirmatory,8487254.0,
318,125789,6,6,,103401109,441074,Active,84028191.0,1565.0,0.08,Ki,Inhibitory effect on Bufuralol 1'-hydroxylation by human liver microsomes (Ki = apparent inhibition constant),Confirmatory,8487254.0,
319,127068,3,4,,103401109,441074,Active,,,,,"Compound was evaluated for ventricular extrasystole activity, 3 min before aconitine infusion, at a dose of 10 mg/kg, intravenously administered in mice; S=significant antiarrhythmic effect",Other,6147415.0,
320,127205,3,4,,103401109,441074,Active,,,,,"Compound was evaluated for ventricular extrasystole, 30 min before aconitine infusion, at a dose of 30 mg/kg, perorally administered in mice; S=significant antiarrhythmic effect",Other,6147415.0,
321,127207,3,4,,103401109,441074,Active,,,,,"Compound was evaluated for ventricular tachycardia activity in intravenously administered mice, 3 min before aconitine infusion, at a dose of 10 mg/kg; S=significant antiarrhythmic effect",Other,6147415.0,
322,127210,3,4,,103401109,441074,Active,,,,,"Compound was evaluated for ventricular tachycardia activity in perorally administered mice, 30 min before aconitine infusion, at a dose of 30 mg/kg; S=significant antiarrhythmic effect",Other,6147415.0,
323,127811,6,2,,103401109,441074,Unspecified,,,,,The compound was tested for effective concentration (intradermal injection) that caused local anesthesia in 50% of mice by tail-clip method,Other,3572966.0,
324,128827,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against aconitine induced initial arrhythmia ) in anesthetized mouse administered perorally,Other,3572966.0,
325,128828,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against aconitine induced initial arrhythmia ) in anesthetized mouse administered through iv(ear or caudal vein),Other,3572966.0,
326,128830,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against aconitine induced ventricular tachycardia) in anesthetized mouse administered perorally,Other,3572966.0,
327,128831,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against aconitine induced ventricular tachycardia) in anesthetized mouse administered through iv(ear or caudal vein),Other,3572966.0,
328,128842,7,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic potency in female roswell park white mice using chloroform-induced ventricular fibrillation assay,Other,7359535.0,
329,134406,6,2,,103401109,441074,Unspecified,,,,,Lethal dose in mice (LD50) (following i.v. dosing),Other,6147415.0,
330,134413,6,2,,103401109,441074,Unspecified,,,,,Compound was evaluated for acute toxicity (24 h) in female roswell park white mice given intraperitoneally,Other,7359535.0,
331,134757,6,2,,103401109,441074,Unspecified,,,,,The compound was tested for acute toxicity when given intraperitoneally in mouse,Other,3572966.0,
332,134765,6,2,,103401109,441074,Unspecified,,,,,Toxicity estimated in mouse as LD50 by intravenous administration,Other,7205883.0,
333,150607,6,7,,103401109,441074,Active,84028191.0,1565.0,0.043,Ki,Inhibition of partially purified cytochrome P450 2D6 1'-hydroxybufuralol formation,Confirmatory,8487254.0,
334,150609,6,7,,103401109,441074,Active,84028191.0,1565.0,0.06,Ki,Inhibitory constant for cytochrome P450 2D6,Confirmatory,8487254.0,
335,150616,9,2,,103401109,441074,Active,,,5.0,Ki,Concentration giving half of the maximal ATPase activity calculated for the high-affinity binding site of the CHO P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
336,150618,9,2,,103401109,441074,Unspecified,,,340.0,IC50,Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model,Confirmatory,12477351.0,
337,150735,9,2,,103401109,441074,Active,,,2.6,Ki,High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
338,150736,3,8,,103401109,441074,Unspecified,,,,,Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Other,12477351.0,
339,150751,7,1,,103401109,441074,Unspecified,,,,,Inhibition of P-glycoprotein using ATPase in MDR1 membranes,Other,12699389.0,
340,150752,6,3,,103401109,441074,Active,,,5.6,IC50,"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
341,150753,6,3,,103401109,441074,Active,,,13.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
342,150754,6,3,,103401109,441074,Active,,,10.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
343,150755,6,3,,103401109,441074,Active,,,2.2,IC50,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Confirmatory,12699389.0,
344,150756,3,7,,103401109,441074,Unspecified,,,,,Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells,Other,12699389.0,
345,151312,3,4,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity estimated by using the ouabain intoxicated dog model and the active dose of base in ouabain dog was reported.,Other,3973901.0,
346,158875,4,3,,103401109,441074,Active,,,0.16,IC50,In vitro antimalarial activity against Plasmodium falciparum W2 in human erythrocytes by [3H]hypoxanthine uptake,Confirmatory,11992775.0,
347,158877,4,3,,103401109,441074,Active,,,0.004,IC50,In vitro inhibition of parasite development of Plasmodium falciparum W2 in human erythrocytes,Confirmatory,11992775.0,
348,161144,4,6,,103401109,441074,Unspecified,,,,,"Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel",Other,8230126.0,
349,161281,10,5,,103401109,441074,Active,7531135.0,3757.0,0.32359,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
350,162809,3,4,,103401109,441074,Unspecified,,,,,Duration of action potential was determined in vitro in Canine Purkinje fibers at 0.1 uM concentration.,Other,2299628.0,
351,162810,3,4,,103401109,441074,Unspecified,,,,,Duration of action potential was determined in vitro in Canine Purkinje fibers at 100 uM concentration.,Other,2299628.0,
352,162812,3,4,,103401109,441074,Unspecified,,,,,Duration of action potential was determined in vitro in Canine Purkinje fibers at 10 uM concentration.,Other,2299628.0,
353,162814,3,4,,103401109,441074,Unspecified,,,,,Duration of action potential was determined in vitro in Canine Purkinje fibers at 1 uM concentration.,Other,2299628.0,
354,162816,3,4,,103401109,441074,Unspecified,,,,,Duration of action potential was determined in vitro in Canine Purkinje fibers at 30 uM concentration.,Other,2299628.0,
355,167266,5,1,,103401109,441074,Unspecified,,,,,Tested in vitro for antiarrhythmic activity in isolated rabbit atria,Other,3572966.0,
356,168225,3,4,,103401109,441074,Unspecified,,,,,"Activity on heart rate in anesthetized rat when induced through femoral vein (iv), at 5 mg/kg",Other,3572966.0,
357,171461,3,4,,103401109,441074,Unspecified,,,,,"The compound was tested for activity on heart rate in anesthetized rat when induced through portal vein (ipv),at 14 mg/kg",Other,3572966.0,
358,171463,5,3,,103401109,441074,Unspecified,,,,,"The compound was tested for blood electrolyte Ca ++ in rat serum when induced through femoral vein (iv), at 20 mg/kg; 0=Inactive",Other,3572966.0,
359,171465,3,4,,103401109,441074,Unspecified,,,,,"The compound was tested for blood electrolyte K+ in rat serum when induced through femoral vein (iv),at 20 mg/kg",Other,3572966.0,
360,171467,5,3,,103401109,441074,Unspecified,,,,,"The compound was tested for blood electrolyte Na+ in rat serum when induced through femoral vein (iv), at 20 mg / kg; 0=Inactive",Other,3572966.0,
361,178119,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against CaCl2 induced ventricular fibrillation ) in conscious rat administered intravenously,Other,3572966.0,
362,178121,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity ( protection against CaCl2 induced ventricular fibrillation ) in conscious rat administered orally (po),Other,3572966.0,
363,178123,6,3,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity (protection against CaCl2 induced ventricular fibrillation) in anesthetized rat administered through portal vein (ipv),Other,3572966.0,
364,180360,6,3,,103401109,441074,Unspecified,,,,,The compound was tested for antiarrhythmic activity ( protection against CaCl2 induced ventricular fibrillation ) in anesthetized rat,Other,3572966.0,
365,184788,6,2,,103401109,441074,Unspecified,,,,,The compound was tested for acute toxicity when given intravenously in rat,Other,3572966.0,
366,205267,9,2,,103401109,441074,Active,,,3.2,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
367,205268,4,7,,103401109,441074,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
368,205279,4,10,,103401109,441074,Unspecified,116452.0,25665.0,,,Percentage inhibition of specific binding of [3H]batrachotoxin [3H]BTX) in sodium channel from cardiac myocytes at 10 uM,Other,8230126.0,
369,218591,4,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as % change for conduction time(CT) at 10 uM at 0.1-100 uM concentration range,Other,3681896.0,
370,218724,4,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as maximum % change for conduction time(CT) at 0.1-100 uM concentration range; concentration at which it occurred is 100 uM.,Other,3681896.0,
371,218734,4,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as % change for the functional refractory period (FRP) at 10 uM at concentration range of 0.1-100 uM,Other,3681896.0,
372,218747,4,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as maximum % change for functional refractory period (FRP) at 0.1-100 uM concentration range; concentration at which it occurred is 100 uM.,Other,3681896.0,
373,218749,3,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as maximum % change for functional refractory period (FRP) at 0.1-100 uM concentration range; concentration at which it occurred is 10 uM.,Other,3681896.0,
374,220506,4,3,,103401109,441074,Unspecified,,,,,In vitro electrophysiological activity in canine cardiac occurred is 100 uM.,Other,3681896.0,
375,220648,3,3,,103401109,441074,Unspecified,,,,,In vitro electrophysiological activity in canine cardiac occurred is 30 uM.,Other,3681896.0,
376,220666,3,3,,103401109,441074,Unspecified,,,,,In vitro electrophysiological activity in canine cardiac occurred is 50 uM.,Other,3681896.0,
377,220798,3,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as % change for action potential duration at 10 uM at 0.1-30 uM concentration range,Other,3681896.0,
378,220801,3,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as % change for action potential duration at 10 uM at 5-50 uM concentration range,Other,3681896.0,
379,220802,4,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as % change for action potential duration at a concentration of 10 uM,Other,3681896.0,
380,220811,4,3,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac occurred is 100 uM.,Other,3681896.0,
381,220821,3,3,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac occurred is 30 uM.,Other,3681896.0,
382,220938,3,3,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac occurred is 100 uM.,Other,3681896.0,
383,220945,3,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as percent change Vmax at 10 uM at concentration range of 0.1-30 uM,Other,3681896.0,
384,220953,3,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as percent change Vmax at 10 uM at concentration range of 5-50 uM,Other,3681896.0,
385,220957,3,4,,103401109,441074,Unspecified,,,,,In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as percent change Vmax at 10 uM at concentration range of 0.1-100 uM,Other,3681896.0,
386,229577,3,3,,103401109,441074,Unspecified,,,,,Ratio of lethal dose to that of effective dose in mice,Other,7359535.0,
387,232313,3,4,,103401109,441074,Unspecified,,,,,EC30 ratio of contractility to atrial rate in isolated guinea pig atria,Other,7452671.0,
388,232314,3,4,,103401109,441074,Unspecified,,,,,EC30 ratio of maximal driving frequency to atrial rate in isolated guinea pig atria,Other,7452671.0,
389,235407,3,4,,103401109,441074,Unspecified,,,,,Therapeutic ratio in mixed-breed or Beagle dogs after intravenous administration of the compound.,Other,7420355.0,
390,237416,3,4,,103401109,441074,Unspecified,,,,,Log D value against bovine serum albumin,Other,15267234.0,
391,237474,3,3,,103401109,441074,Unspecified,,,,,Percentage of drug bound in bovine plasma albumin,Other,15267234.0,
392,238250,6,6,,103401109,441074,Active,,,0.03,Ki,Binding affinity for cytochrome P450 2D6,Confirmatory,15481972.0,
393,239884,4,2,,103401109,441074,Unspecified,,,,,pKa value of the compound,Other,15267234.0,
394,240619,6,6,,103401109,441074,Active,,,0.01,IC50,Inhibitory concentration against cytochrome P450 2D6,Confirmatory,15481972.0,
395,241212,8,2,,103401109,441074,Unspecified,,,240.0,IC50,Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes,Confirmatory,15225721.0,
396,243151,7,2,,103401109,441074,Active,,,0.32359,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
397,262715,4,9,,103401109,441074,Active,84028191.0,1565.0,0.02,IC50,Inhibition of human CYP2D6,Confirmatory,16570918.0,
398,275596,3,5,,103401109,441074,Unspecified,,,,,Activity against alternating current-induced arrhythmia in guinea pig left atrium at 50 uM,Other,17228875.0,
399,275601,3,5,,103401109,441074,Unspecified,,,,,Negative inotropic activity assessed as decrease in developed tension in isolated guinea pig left atrium at 50 uM relative to control,Other,17228875.0,
400,275612,3,5,,103401109,441074,Unspecified,,,,,Negative chronotropic activity assessed as decrease in atrial rate in isolated guinea pig right atrium at 50 uM relative to control,Other,17228875.0,
401,275614,3,4,,103401109,441074,Unspecified,,,,,Inhibition of calcium-induced contraction of potassium ion depolarized guinea pig aortic strips at 100 uM,Other,17228875.0,
402,275616,3,4,,103401109,441074,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
403,275617,3,4,,103401109,441074,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
404,275618,3,4,,103401109,441074,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
405,275619,3,4,,103401109,441074,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
406,275620,3,4,,103401109,441074,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
407,275621,3,4,,103401109,441074,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
408,275622,3,4,,103401109,441074,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
409,275623,3,4,,103401109,441074,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
410,275624,3,4,,103401109,441074,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 0.1uM,Other,17228875.0,
411,275625,3,4,,103401109,441074,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 0.1 uM,Other,17228875.0,
412,275626,3,4,,103401109,441074,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 0.1 uM,Other,17228875.0,
413,275627,3,4,,103401109,441074,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 0.1 uM,Other,17228875.0,
414,275628,3,4,,103401109,441074,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
415,275629,3,4,,103401109,441074,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
416,275630,3,4,,103401109,441074,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
417,275631,3,4,,103401109,441074,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
418,275632,3,4,,103401109,441074,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
419,275633,3,4,,103401109,441074,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
420,275634,3,4,,103401109,441074,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
421,275635,3,4,,103401109,441074,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
422,275636,6,4,,103401109,441074,Active,,,10.26,EC50,Activity against alternating current-induced arrhythmia in guinea pig left atrium,Confirmatory,17228875.0,
423,275639,6,4,,103401109,441074,Active,,,3.38,EC50,Negative inotropic activity assessed as decrease in developed tension in isolated guinea pig left atrium,Confirmatory,17228875.0,
424,275640,6,4,,103401109,441074,Active,,,3.99,EC50,Negative chronotropic activity assessed as decrease in atrial rate in isolated guinea pig right atrium,Confirmatory,17228875.0,
425,277231,6,7,,103401109,441074,Active,84028191.0,1565.0,0.41,IC50,Inhibition of CYP2D6 in human liver microsomes,Confirmatory,17249648.0,
426,278900,6,5,,103401109,441074,Unspecified,123526.0,,325.0,IC50,Inhibition of Tween 20-induced beta-hematin formation by colorimetric assay,Confirmatory,17088494.0,
427,288771,8,1,,103401109,441074,Unspecified,,,,,CNS toxicity in iv dosed Sprague-Dawley rat assessed as cumulative convulsion dose,Other,17506538.0,
428,288772,9,1,,103401109,441074,Unspecified,,,,,Hemodynamic effect in intravenously dosed Sprague-Dawley rat with ischemia-induced arrhythmia assessed as dose producing 25% reduction in systemic blood pressure,Other,17506538.0,
429,288773,9,1,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in intravenously dosed Sprague-Dawley rat with ischemia-induced arrhythmia,Other,17506538.0,
430,288775,9,1,,103401109,441074,Unspecified,,,,,Effect on blood pressure in intravenously dosed Sprague-Dawley rat assessed as dose producing 25% change in arterial blood pressure,Other,17506538.0,
431,288776,9,1,,103401109,441074,Unspecified,,,,,Effect on ECG parameters in intravenously dosed Sprague-Dawley rat assessed as dose producing 25% prolongation of P-R interval,Other,17506538.0,
432,288777,9,1,,103401109,441074,Unspecified,,,,,Effect on ECG parameters in intravenously dosed Sprague-Dawley rat assessed as dose producing 25% lengthening in QT1 interval,Other,17506538.0,
433,288778,9,1,,103401109,441074,Unspecified,,,,,Effect on ECG parameters in intravenously dosed Sprague-Dawley rat assessed as dose producing 25% lengthening in QT2 interval,Other,17506538.0,
434,288779,9,1,,103401109,441074,Unspecified,,,,,Effect on electrical stimulation in intravenously dosed Sprague-Dawley rat assessed as dose producing 25% prolongation of in current threshold for induction of extrasystole,Other,17506538.0,
435,288780,9,1,,103401109,441074,Unspecified,,,,,Effect on electrical stimulation in intravenously dosed Sprague-Dawley rat assessed as dose producing 25% increase in effective refractory period,Other,17506538.0,
436,288781,8,2,,103401109,441074,Unspecified,,,,,Toxicity in intravenously dosed CD1 mouse,Other,17506538.0,
437,288782,9,5,,103401109,441074,Active,215273881.0,6331.0,6.9,IC50,Inhibition of human heart sodium channel Nav1.5 by patch-clamp method,Confirmatory,17506538.0,
438,288783,9,5,,103401109,441074,Active,146345443.0,3741.0,7.3,IC50,Inhibition of human potassium channel Kv1.5 by patch-clamp method,Confirmatory,17506538.0,
439,288784,9,5,,103401109,441074,Active,38257805.0,65180.0,2.2,IC50,Inhibition of rat potassium channel Kv4.2 by patch-clamp method,Confirmatory,17506538.0,
440,288785,9,5,,103401109,441074,Inconclusive,24418849.0,25736.0,,IC50,Inhibition of rat potassium channel Kv2.1 by patch-clamp method,Confirmatory,17506538.0,
441,298287,8,1,,103401109,441074,Active,,,5.0,IC50,Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation,Confirmatory,17850126.0,
442,311524,4,3,,103401109,441074,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
443,318315,6,7,,103401109,441074,Active,84028191.0,1565.0,0.011000000000000001,IC50,Inhibition of human CYP2D6,Confirmatory,18324762.0,
444,361985,3,4,,103401109,441074,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method",Other,18666772.0,
445,361986,3,4,,103401109,441074,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by shake flask method",Other,18666772.0,
446,362135,5,7,,103401109,441074,Active,84028191.0,1565.0,0.013999999999999999,IC50,Inhibition of human recombinant CYP2D6 expressed in insect microsomes,Confirmatory,18672861.0,
447,364761,4,9,,103401109,441074,Active,84028191.0,1565.0,0.013999999999999999,IC50,Inhibition of human recombinant CYP2D6 expressed in baculovirus-infected insect microsomes,Confirmatory,18763754.0,
448,367395,3,9,,103401109,441074,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 at 100 uM by LC/ESI-MS analysis,Other,19117415.0,
449,367396,3,9,,103401109,441074,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 at 100 uM by LC/ESI-MS analysis,Other,19117415.0,
450,367397,3,10,,103401109,441074,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 at 100 uM by LC/ESI-MS analysis,Other,19117415.0,
451,367398,8,2,,103401109,441074,Active,84028191.0,1565.0,0.0196,IC50,Inhibition of human CYP2D6 expressed in baculovirus-infected insect cell system,Confirmatory,19117415.0,
452,367399,8,2,,103401109,441074,Active,84028191.0,1565.0,0.0098,Ki,Inhibition of human CYP2D6 by Lineweaver-Burke plot,Confirmatory,19117415.0,
453,370290,3,9,,103401109,441074,Unspecified,84028191.0,1565.0,,,Effect on CYP2D6 in human liver assessed as bufuralol 19-hydroxylation at 100 uM relative to control,Other,17132069.0,
454,373867,6,3,,103401109,441074,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
455,378129,6,7,,103401109,441074,Active,84028191.0,1565.0,0.08199999999999999,IC50,Inhibition of human liver microsome CYP2D6 in assessed as [14C]formaldehyde formation,Confirmatory,15679319.0,
456,386623,4,8,,103401109,441074,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
457,386625,9,5,,103401109,441074,Unspecified,313104181.0,6580.0,113.8,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
458,389817,6,7,,103401109,441074,Active,84028191.0,1565.0,14.0,IC50,Inhibition of human recombinant CYP2D6 expressed in baculovirus-infected insect microsomes,Confirmatory,19049427.0,
459,392048,12,1,,103401109,441074,Unspecified,,,,EC50,Cardiotoxicity in iv dosed Dunkin-Hartley guinea pig assessed as drug level required to evoke 50 ms QTc prolongation administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG,Confirmatory,18262683.0,
460,392049,3,4,,103401109,441074,Unspecified,,,,,"Cardiotoxicity in Dunkin-Hartley guinea pig assessed as maximal QTc prolongation time at 10 mg/kg, iv administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG",Other,18262683.0,
461,396379,4,3,,103401109,441074,Active,,,0.051,IC50,Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by [G-3H]hypoxanthine uptake,Confirmatory,18395298.0,
462,401285,3,3,,103401109,441074,Active,,,,,Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as increase in rhodamine 6G accumulation,Other,8984151.0,
463,402937,6,7,,103401109,441074,Active,84028191.0,1565.0,0.078,IC50,Inhibition of human CYP2D6 by radiometric assay,Confirmatory,15270556.0,
464,404304,3,10,,103401109,441074,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
465,408340,8,5,,103401109,441074,Active,7531135.0,3757.0,0.32359,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
466,415383,3,9,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of human recombinant CYP2D6 at 5 uM assessed as blockade of O-demethylation of dextromethorphan in to dextrophan by nanoscale automated in-capillary assay,Other,19326942.0,
467,415384,4,8,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of human recombinant CYP2D6 assessed as blockade of O-demethylation of dextromethorphan in to dextrophan by nanoscale automated in-capillary assay,Other,19326942.0,
468,425652,7,2,,103401109,441074,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
469,425653,7,2,,103401109,441074,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
470,434955,1,2,,56320931,441074,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
471,434959,1,1,,85788831,441074,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
472,434962,1,2,,56320931,441074,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
473,434989,1,1,,56320931,441074,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
474,435005,1,1,,56320931,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
475,435030,1,2,,56320931,441074,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
476,435030,1,2,,56320931,441074,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
477,444050,7,1,,103401109,441074,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
478,444051,6,2,,103401109,441074,Unspecified,,,,,Total clearance in human,Other,20070106.0,
479,444052,6,2,,103401109,441074,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
480,444053,6,2,,103401109,441074,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
481,444054,6,1,,103401109,441074,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
482,444055,3,3,,103401109,441074,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
483,444056,3,3,,103401109,441074,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
484,444057,3,3,,103401109,441074,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
485,444058,6,2,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
486,449703,5,2,,103401109,441074,Active,,,0.009590000000000001,EC50,NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
487,449704,5,2,,103401109,441074,Active,,,0.0352,EC50,NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
488,449705,5,2,,103401109,441074,Unspecified,,,50.75,CC50,NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7),Confirmatory,18579783.0,
489,449706,5,2,,103401109,441074,Unspecified,,,,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.",Other,18579783.0,
490,449728,1,2,,56320931,441074,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
491,449762,1,2,,56320931,441074,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
492,455986,3,5,,103401109,441074,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
493,463079,1,2,,56320931,441074,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
494,463082,1,1,,56320931,441074,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
495,463111,1,1,,56320931,441074,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
496,463141,1,2,,56320931,441074,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
497,463165,1,1,,56320931,441074,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
498,463210,1,2,,56320931,441074,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
499,463254,1,1,,56320931,441074,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
500,467611,3,6,,103401109,441074,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
501,467612,3,6,,103401109,441074,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
502,467613,5,3,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
503,476929,3,3,,103401109,441074,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
504,485270,1,1,,56320931,441074,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
505,485272,1,1,,56320931,441074,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
506,485275,1,3,,56320931,441074,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
507,485290,1,1,,17389531,441074,Inconclusive,20150581.0,,0.0316,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
508,485294,1,1,,56320931,441074,Inconclusive,119389684.0,,8.9125,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
509,485297,1,1,,56320931,441074,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
510,485298,1,1,,56320931,441074,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
511,485313,1,2,,56320931,441074,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
512,485317,1,2,,56320931,441074,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
513,485341,1,1,,56320931,441074,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
514,485344,1,1,,56320931,441074,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
515,485347,1,2,,56320931,441074,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
516,485349,1,1,,56320931,441074,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
517,485358,1,1,,56320931,441074,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
518,485360,1,1,,56320931,441074,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
519,485364,1,1,,56320931,441074,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
520,485367,1,2,,56320931,441074,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
521,488837,1,1,,56320931,441074,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
522,488839,1,1,,56320932,441074,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
523,488839,1,1,,56320932,441074,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
524,488847,1,3,,56320931,441074,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
525,488862,1,1,,56320932,441074,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
526,488890,1,2,,56320931,441074,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
527,488895,1,2,,56320932,441074,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
528,488896,1,1,,56320932,441074,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
529,488899,1,1,,56320932,441074,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
530,488922,1,2,,56320931,441074,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
531,488965,1,2,,56320932,441074,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
532,488966,1,1,,56320932,441074,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
533,488975,1,2,,56320931,441074,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
534,488977,1,2,,56320931,441074,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
535,491138,3,4,,103401109,441074,Unspecified,,,,,Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 50 uM,Other,20509610.0,
536,491140,5,3,,103401109,441074,Active,,,3.99,EC50,Negative chronotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate,Confirmatory,20509610.0,
537,491141,5,3,,103401109,441074,Active,,,3.38,EC50,Negative inotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease in developed tension,Confirmatory,20509610.0,
538,491145,3,4,,103401109,441074,Unspecified,,,,,Negative chronotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate at 50 uM relative to control,Other,20509610.0,
539,491151,3,4,,103401109,441074,Unspecified,,,,,Negative inotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease in developed tension at 50 uM relative to control,Other,20509610.0,
540,491152,5,3,,103401109,441074,Active,,,10.26,EC50,Antiarrhythmic activity in sinusoidal alternating current-induced guinea pig left atrium assessed as increase in current strength at which extra beats occur measured every 30 mins,Confirmatory,20509610.0,
541,491158,3,4,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in sinusoidal alternating current-induced guinea pig left atrium assessed as increase in current strength at which extra beats occur at 50 uM measured every 30 mins,Other,20509610.0,
542,491159,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 10 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
543,491160,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 1 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
544,491161,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 1 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
545,492881,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 0.1 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
546,492882,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 0.01 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
547,492883,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 0.001 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
548,492884,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 10 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
549,492885,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 1 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
550,492886,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 0.1 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
551,492887,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 0.01 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
552,492888,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 0.001 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
553,492889,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 10 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
554,492890,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 0.1 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
555,492891,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 0.01 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
556,492892,3,4,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 0.001 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
557,492893,3,5,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 0.001 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
558,492894,3,5,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 0.01 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
559,492895,3,5,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 0.1 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
560,492896,3,5,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 1 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
561,492897,3,5,,103401109,441074,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 10 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
562,492947,1,1,,56320931,441074,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
563,492953,1,1,,56320932,441074,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
564,492956,1,1,,56320932,441074,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
565,492972,1,1,,56320932,441074,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
566,493005,1,1,,56320932,441074,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
567,493008,1,1,,56320932,441074,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
568,493008,1,1,,56320932,441074,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
569,493008,1,1,,56320932,441074,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
570,493008,1,1,,56320932,441074,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
571,493011,1,1,,56320931,441074,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
572,493012,1,1,,56320931,441074,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
573,493014,1,1,,56320931,441074,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
574,493036,1,2,,56320931,441074,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
575,493056,1,1,,56320931,441074,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
576,493084,1,1,,56320931,441074,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
577,493087,1,1,,56320932,441074,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
578,493091,1,1,,56320932,441074,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
579,493098,1,1,,56320932,441074,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
580,493131,1,1,,56320932,441074,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
581,493160,1,1,,56320932,441074,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
582,493187,1,2,,56320932,441074,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
583,493244,1,1,,56320932,441074,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
584,493244,1,1,,56320932,441074,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
585,493244,1,1,,56320932,441074,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
586,493244,1,1,,56320932,441074,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
587,496819,4,2,,103401109,441074,Active,,,24.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
588,504326,1,2,,56320932,441074,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
589,504326,1,2,,56320932,441074,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
590,504327,1,1,,56320931,441074,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
591,504329,1,1,,56320932,441074,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
592,504332,1,1,,56320931,441074,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
593,504333,1,1,,56320931,441074,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
594,504339,1,1,,56320932,441074,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
595,504357,1,1,,56320932,441074,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
596,504357,1,1,,56320932,441074,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
597,504406,1,1,,56320931,441074,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
598,504408,2,1,,56320931,441074,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
599,504411,1,1,,56320932,441074,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
600,504414,1,1,,56320932,441074,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
601,504414,1,1,,56320932,441074,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
602,504423,1,1,,56320932,441074,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
603,504441,1,1,,56320932,441074,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
604,504444,1,1,,56320932,441074,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
605,504454,1,3,,56320932,441074,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
606,504462,1,1,,56320932,441074,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
607,504466,1,1,,56320931,441074,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
608,504467,1,1,,56320931,441074,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
609,504490,1,2,,56320932,441074,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
610,504523,1,1,,56320932,441074,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
611,504523,1,1,,56320932,441074,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
612,504558,1,1,,56320932,441074,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
613,504577,2,2,,56320932,441074,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
614,504582,2,1,,56320932,441074,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
615,504621,1,1,,56320932,441074,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
616,504634,1,1,,56320932,441074,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
617,504648,1,1,,56320932,441074,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
618,504651,1,1,,56320931,441074,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
619,504652,1,1,,56320931,441074,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
620,504660,1,1,,56320931,441074,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
621,504690,1,3,,56320932,441074,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
622,504692,2,2,,56320932,441074,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
623,504700,1,1,,56320932,441074,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
624,504700,1,1,,56320932,441074,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
625,504706,1,1,,56320931,441074,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
626,504707,1,1,,56320932,441074,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
627,504707,1,1,,56320932,441074,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
628,504720,1,1,,56320932,441074,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
629,504734,1,1,,56320932,441074,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
630,504766,2,1,,56320932,441074,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
631,504775,1,1,,56320932,441074,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
632,504803,1,1,,56320932,441074,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
633,504810,1,2,,56320931,441074,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
634,504812,1,2,,56320931,441074,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
635,504832,1,1,,56320931,441074,Active,,,0.0294,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
636,504834,1,1,,56320931,441074,Active,,,0.0208,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
637,504842,1,1,,56320931,441074,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
638,504845,1,1,,56320932,441074,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
639,504847,1,1,,56320932,441074,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
640,504848,1,1,,56320931,441074,Active,,,0.0251,Potency,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
641,504850,1,1,,56320931,441074,Active,,,0.0355,Potency,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
642,504884,1,2,,56320932,441074,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
643,504891,1,1,,56320932,441074,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
644,504894,1,1,,56320932,441074,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
645,504937,1,2,,56320932,441074,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
646,513158,5,2,,103401109,441074,Active,,,,IC50,Inhibition of heme crystallization after 16 hrs,Confirmatory,16816845.0,
647,513176,1,3,,103401109,441074,Active,,,,,Displacement of [3H]astemizole from free heme crystal at 15 uM after 16 hrs by scintillation counting,Other,16816845.0,
648,537733,2,3,,103401109,441074,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
649,537734,5,2,,103401109,441074,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
650,537735,2,3,,103401109,441074,Active,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
651,537736,5,2,,103401109,441074,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
652,540209,4,3,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
653,540210,4,3,,103401109,441074,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
654,540211,2,5,,103401109,441074,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
655,540212,4,3,,103401109,441074,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
656,540213,4,3,,103401109,441074,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
657,540214,4,3,,103401109,441074,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
658,540215,3,2,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
659,540216,4,3,,103401109,441074,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
660,540217,4,3,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
661,540218,4,3,,103401109,441074,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
662,540219,4,3,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
663,540220,4,3,,103401109,441074,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
664,540221,4,3,,103401109,441074,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
665,540234,2,5,,103401109,441074,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
666,540253,1,1,,56320932,441074,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
667,540253,1,1,,56320932,441074,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
668,540253,1,1,,56320932,441074,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
669,540263,1,1,,56320932,441074,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
670,540263,1,1,,56320932,441074,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
671,540267,1,1,,56320932,441074,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
672,540275,1,1,,56320931,441074,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
673,540277,1,1,,56320931,441074,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
674,540295,1,1,,56320932,441074,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
675,540303,1,1,,56320932,441074,Inactive,6679377.0,18792.0,1.2589,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
676,540303,1,1,,56320932,441074,Inactive,7242179.0,18793.0,1.2589,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
677,540303,1,1,,56320932,441074,Inactive,257471003.0,18815.0,1.2589,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
678,540308,1,1,,56320932,441074,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
679,540317,1,1,,56320932,441074,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
680,540336,1,1,,56320932,441074,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
681,540336,1,1,,56320932,441074,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
682,540364,1,2,,56320932,441074,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
683,565894,2,6,,103401109,441074,Active,,,,,Metabolic stability in rat liver microsomes in presence of CYP2D6 inhibitor quinidine,Other,21144625.0,
684,566791,4,7,,103401109,441074,Active,84028191.0,1565.0,0.01,IC50,Inhibition of human CYP2D6,Confirmatory,21189020.0,
685,568747,4,5,,103401109,441074,Active,,,0.01,IC50,Inhibition of CYP2D6 after 30 mins by fluorometric assay,Confirmatory,21138310.0,
686,588208,2,3,,103401109,441074,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
687,588209,2,3,,103401109,441074,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
688,588210,2,4,,103401109,441074,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
689,588211,2,3,,103401109,441074,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
690,588212,2,3,,103401109,441074,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
691,588213,2,3,,103401109,441074,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
692,588214,2,3,,103401109,441074,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
693,588215,2,3,,103401109,441074,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
694,588216,2,3,,103401109,441074,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
695,588217,2,3,,103401109,441074,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
696,588218,2,3,,103401109,441074,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
697,588219,2,3,,103401109,441074,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
698,588220,2,3,,103401109,441074,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
699,588334,1,1,,56320932,441074,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
700,588335,1,1,,56320932,441074,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
701,588342,1,1,,56320931,441074,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
702,588352,1,2,,56320932,441074,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
703,588354,1,1,,56320932,441074,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
704,588358,1,2,,56320932,441074,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
705,588391,1,1,,56320932,441074,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
706,588405,1,1,,56320932,441074,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
707,588413,1,2,,56320932,441074,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
708,588436,1,1,,56320932,441074,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
709,588453,1,1,,56320932,441074,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
710,588456,1,1,,56320932,441074,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
711,588458,1,1,,56320932,441074,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
712,588473,1,1,,56320932,441074,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
713,588473,1,1,,56320932,441074,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
714,588475,1,2,,56320932,441074,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
715,588475,1,2,,56320932,441074,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
716,588478,1,2,,124800942,441074,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
717,588489,1,1,,56320932,441074,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
718,588492,1,1,,56320932,441074,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
719,588493,1,2,,56320932,441074,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
720,588497,1,2,,56320932,441074,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
721,588497,1,2,,56320932,441074,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
722,588497,1,2,,56320932,441074,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
723,588499,1,3,,56320932,441074,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
724,588499,1,3,,56320932,441074,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
725,588499,1,3,,56320932,441074,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
726,588501,1,2,,56320932,441074,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
727,588501,1,2,,56320932,441074,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
728,588501,1,2,,56320932,441074,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
729,588511,1,2,,56320931,441074,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
730,588513,1,1,,17389531,441074,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
731,588514,1,1,,17389531,441074,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
732,588515,1,1,,17389531,441074,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
733,588516,1,1,,17389531,441074,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
734,588526,1,1,,17389531,441074,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
735,588527,1,1,,17389531,441074,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
736,588532,1,1,,17389531,441074,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
737,588533,1,1,,17389531,441074,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
738,588534,1,1,,17389531,441074,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
739,588535,1,1,,17389531,441074,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
740,588536,1,1,,17389531,441074,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
741,588537,1,1,,17389531,441074,Inconclusive,216409692.0,5468.0,44.6684,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
742,588541,1,1,,17389531,441074,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
743,588543,1,1,,17389531,441074,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
744,588544,1,1,,17389531,441074,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
745,588545,1,1,,17389531,441074,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
746,588546,1,1,,17389531,441074,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
747,588547,1,1,,17389531,441074,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
748,588549,1,1,,56320932,441074,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
749,588579,1,1,,56320932,441074,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
750,588590,1,1,,56320932,441074,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
751,588591,1,1,,56320932,441074,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
752,588621,1,1,,56320932,441074,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
753,588627,1,1,,56320931,441074,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
754,588664,1,2,,56320932,441074,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
755,588664,1,2,,56320932,441074,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
756,588674,1,2,,56320932,441074,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
757,588675,1,1,,56320931,441074,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
758,588676,1,1,,56320931,441074,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
759,588689,1,1,,56320932,441074,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
760,588692,2,1,,56320932,441074,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
761,588726,1,2,,56320932,441074,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
762,588727,1,1,,56320932,441074,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
763,588795,1,1,,56320932,441074,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
764,588814,1,3,,56320932,441074,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
765,588819,1,4,,56320932,441074,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
766,588834,2,1,,17389531,441074,Active,325651834.0,3757.0,7.9433,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
767,588850,1,1,,56320932,441074,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
768,588852,1,3,,56320932,441074,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
769,588855,1,1,,56320932,441074,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
770,588856,1,1,,56320932,441074,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
771,588985,1,9,,103401109,441074,Unspecified,313104182.0,6582.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OCT2",Other,20190787.0,
772,588988,1,9,,103401109,441074,Unspecified,313104181.0,6580.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OCT1",Other,20190787.0,
773,588991,1,9,,103401109,441074,Unspecified,74731723.0,55244.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MATE1",Other,20190787.0,
774,588992,1,9,,103401109,441074,Unspecified,74727585.0,146802.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MATE2-K",Other,20190787.0,
775,588993,1,11,,103401109,441074,Unspecified,238054374.0,5243.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MDR1",Other,20190787.0,
776,589039,1,10,,103401109,441074,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
777,589047,1,10,,103401109,441074,Unspecified,84028191.0,1565.0,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
778,592055,1,10,,103401109,441074,Active,84028191.0,1565.0,0.013999999999999999,IC50,Inhibition of human CYP2D6 expressed in baculovirus-infected insect microsomes,Confirmatory,21384875.0,
779,592682,1,4,,103401109,441074,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
780,592683,1,4,,103401109,441074,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
781,602118,1,4,,103401109,441074,Active,,,,,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.",Other,22096101.0,
782,602123,1,1,,56320932,441074,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
783,602141,1,1,,56320932,441074,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
784,602162,1,1,,56320932,441074,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
785,602163,1,1,,56320932,441074,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
786,602179,1,2,,56320932,441074,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
787,602229,1,1,,56320932,441074,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
788,602233,1,1,,56320932,441074,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
789,602244,1,2,,56320932,441074,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
790,602247,1,2,,56320932,441074,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
791,602248,1,2,,56320932,441074,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
792,602250,1,2,,56320932,441074,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
793,602252,1,1,,56320932,441074,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
794,602252,1,1,,56320932,441074,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
795,602261,1,1,,56320932,441074,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
796,602274,1,2,,56320932,441074,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
797,602281,1,1,,56320932,441074,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
798,602281,1,1,,56320932,441074,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
799,602310,1,2,,56320932,441074,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
800,602313,1,1,,56320932,441074,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
801,602329,1,1,,56320932,441074,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
802,602332,1,1,,56320932,441074,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
803,602340,1,2,,56320932,441074,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
804,602342,2,1,,56320932,441074,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
805,602346,1,1,,56320932,441074,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
806,602363,1,1,,56320932,441074,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
807,602393,1,1,,56320932,441074,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
808,602396,1,2,,56320932,441074,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
809,602399,1,2,,56320932,441074,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
810,602405,1,1,,56320932,441074,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
811,602410,1,1,,56320932,441074,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
812,602429,1,1,,56320932,441074,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
813,602438,1,1,,56320932,441074,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
814,602440,1,1,,56320932,441074,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
815,602449,1,2,,56320932,441074,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
816,602481,1,1,,56320932,441074,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
817,603953,1,3,,103401109,441074,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
818,604823,1,4,,103401109,441074,Unspecified,,,,,Plasma protein binding in human at 10 uM,Other,21080703.0,
819,604824,1,4,,103401109,441074,Unspecified,,,,,Plasma protein binding in mouse at 10 uM,Other,21080703.0,
820,612640,1,9,,103401109,441074,Unspecified,7531135.0,3757.0,,,Inhibition of human ERG expressed in HEK293 cells assessed as inhibition of tail current at holding potential of -70 mV at 20 uM after 10 mins by whole-cell patch clamp method,Other,21752640.0,
821,623870,1,1,,56320932,441074,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
822,623870,1,1,,56320932,441074,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
823,623877,1,1,,56320932,441074,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
824,623901,1,1,,56320932,441074,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
825,624037,1,3,,56320932,441074,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
826,624038,1,3,,56320932,441074,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
827,624040,1,3,,56320932,441074,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
828,624101,1,2,,85788831,441074,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
829,624125,1,4,,56320932,441074,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
830,624126,1,3,,56320932,441074,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
831,624127,1,2,,56320932,441074,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
832,624136,1,1,,85788831,441074,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
833,624137,1,1,,85788831,441074,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
834,624138,1,1,,85788831,441074,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
835,624139,1,1,,85788831,441074,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
836,624141,1,1,,85788831,441074,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
837,624151,1,1,,85788831,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
838,624156,1,1,,85788831,441074,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
839,624168,1,1,,56320932,441074,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
840,624169,1,1,,56320932,441074,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
841,624170,1,1,,56320932,441074,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
842,624171,1,1,,56320932,441074,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
843,624172,1,1,,56320932,441074,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
844,624173,1,3,,56320932,441074,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
845,624178,1,1,,56320932,441074,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
846,624202,1,1,,56320932,441074,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
847,624204,1,2,,56320932,441074,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
848,624246,1,1,,56320932,441074,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
849,624256,1,2,,56320932,441074,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
850,624260,1,1,,85788831,441074,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
851,624263,1,1,,56320932,441074,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
852,624263,1,1,,56320932,441074,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
853,624267,1,2,,56320932,441074,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
854,624267,1,2,,56320932,441074,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
855,624268,1,3,,56320932,441074,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
856,624288,1,1,,56320932,441074,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
857,624296,1,1,,56320932,441074,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
858,624297,1,1,,56320932,441074,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
859,624304,1,2,,56320932,441074,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
860,624330,1,2,,56320932,441074,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
861,624349,1,2,,121362609,441074,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
862,624352,1,1,,56320932,441074,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
863,624354,1,1,,56320932,441074,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
864,624377,1,1,,56320932,441074,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
865,624414,1,1,,56320932,441074,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
866,624415,1,2,,56320932,441074,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
867,624416,1,1,,56320932,441074,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
868,624417,1,1,,56320932,441074,Inconclusive,1724069.0,2740.0,17.7828,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
869,624418,1,1,,56320932,441074,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
870,624463,1,1,,56320932,441074,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
871,624464,1,1,,56320932,441074,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
872,624465,1,1,,56320932,441074,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
873,624466,1,3,,56320932,441074,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
874,624467,1,1,,56320932,441074,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
875,624483,1,1,,56320932,441074,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
876,624622,3,1,,103401109,441074,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
877,624623,3,1,,103401109,441074,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
878,624626,1,9,,103401109,441074,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
879,624628,1,9,,103401109,441074,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
880,624629,1,9,,103401109,441074,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
881,625279,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
882,625280,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
883,625281,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
884,625282,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
885,625283,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
886,625284,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
887,625285,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
888,625286,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
889,625287,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
890,625288,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
891,625289,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
892,625290,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
893,625291,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
894,625292,1,3,,103401109,441074,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
895,651548,1,1,,85788831,441074,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
896,651550,1,1,,56320932,441074,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
897,651560,1,1,,56320932,441074,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
898,651572,1,2,,56320932,441074,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
899,651582,1,1,,56320932,441074,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
900,651602,1,1,,56320932,441074,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
901,651602,1,1,,56320932,441074,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
902,651602,1,1,,56320932,441074,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
903,651610,2,1,,56320932,441074,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
904,651635,1,3,,56320932,441074,Inconclusive,171543895.0,6311.0,35.4813,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
905,651636,1,1,,56320932,441074,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
906,651640,1,1,,56320932,441074,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
907,651644,1,1,,56320932,441074,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
908,651647,1,1,,56320932,441074,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
909,651654,1,1,,56320932,441074,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
910,651658,1,1,,56320932,441074,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
911,651661,2,1,,56320932,441074,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
912,651687,1,1,,56320932,441074,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
913,651699,1,1,,56320932,441074,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
914,651699,1,1,,56320932,441074,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
915,651702,1,2,,56320932,441074,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
916,651704,2,1,,56320932,441074,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
917,651710,1,1,,56320932,441074,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
918,651711,2,1,,56320932,441074,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
919,651718,1,2,,56320932,441074,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
920,651719,1,2,,56320932,441074,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
921,651723,1,1,,56320932,441074,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
922,651724,1,1,,56320932,441074,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
923,651725,1,1,,56320932,441074,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
924,651741,1,1,,17389531,441074,Inconclusive,20149576.0,4780.0,14.9601,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
925,651743,1,1,,17389531,441074,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
926,651749,1,1,,17389531,441074,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
927,651751,1,1,,17389531,441074,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
928,651754,1,1,,17389531,441074,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
929,651755,1,1,,17389531,441074,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
930,651757,1,1,,17389531,441074,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
931,651758,1,1,,17389531,441074,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
932,651768,1,2,,56320932,441074,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
933,651777,1,1,,17389531,441074,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
934,651778,1,1,,17389531,441074,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
935,651800,1,1,,56320932,441074,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
936,651802,1,1,,17389531,441074,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
937,651819,1,1,,56320932,441074,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
938,651820,1,1,,56320931,441074,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
939,651820,1,1,,56320932,441074,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
940,651821,2,4,,56320932,441074,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
941,651828,1,2,,121362609,441074,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
942,651838,1,1,,17389531,441074,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
943,651838,1,1,1.0,17389531,441074,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
944,651838,1,1,2.0,17389531,441074,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
945,651838,1,1,3.0,17389531,441074,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
946,651838,1,1,4.0,17389531,441074,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
947,651838,1,1,5.0,17389531,441074,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
948,651838,1,1,6.0,17389531,441074,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
949,651838,1,1,7.0,17389531,441074,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
950,651838,1,1,8.0,17389531,441074,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
951,651957,1,1,,56320932,441074,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
952,651958,1,1,,56320932,441074,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
953,651965,1,1,,56320932,441074,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
954,651999,1,1,,56320932,441074,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
955,652010,1,1,,56320932,441074,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
956,652017,1,1,,56320932,441074,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
957,652025,1,1,,56320932,441074,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
958,652039,1,1,,56320932,441074,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
959,652048,1,2,,56320932,441074,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
960,652051,1,1,,56320932,441074,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
961,652054,1,1,,56320932,441074,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
962,652067,1,4,,56320932,441074,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
963,652104,1,1,,56320932,441074,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
964,652105,1,1,,56320932,441074,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
965,652106,1,1,,56320932,441074,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
966,652115,1,1,,56320932,441074,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
967,652126,1,3,,56320932,441074,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
968,652154,1,1,,56320932,441074,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
969,652162,2,1,,56320932,441074,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
970,652163,1,1,,56320932,441074,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
971,652197,1,1,,56320932,441074,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
972,652257,1,1,,56320932,441074,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
973,655929,1,5,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in guinea pig left atria assessed as increase of 1 Hz-induced alternating current arrhythmia at 5 x 10'-5 M after 60 mins relative to control,Other,22191686.0,
974,655931,2,4,,103401109,441074,Active,,,10.26,EC50,Antiarrhythmic activity in guinea pig left atria assessed as increase of 1 Hz-induced alternating current arrhythmia after 60 mins,Confirmatory,22191686.0,
975,655935,1,5,,103401109,441074,Unspecified,,,,,Negative inotropic activity in guinea pig left atria assessed as decrease of 1 Hz current-induced developed tension at 5 x 10'-5 M relative to control,Other,22191686.0,
976,655940,2,4,,103401109,441074,Active,,,3.38,EC50,Negative inotropic activity in guinea pig left atria assessed as decrease of 1 Hz current-induced developed tension,Confirmatory,22191686.0,
977,655941,1,5,,103401109,441074,Active,,,,,Negative chronotropic activity in guinea pig spontaneously beating right atria assessed as decrease in atrial rate,Other,22191686.0,
978,655942,1,3,,103401109,441074,Unspecified,,,,,Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 10'-4 M,Other,22191686.0,
979,655948,1,5,,103401109,441074,Unspecified,,,,,Negative chronotropic activity in guinea pig spontaneously beating right atria assessed as decrease in atrial rate at 5 x 10'-5 M relative to control,Other,22191686.0,
980,660168,2,2,,103401109,441074,Unspecified,,,130.0,IC50,Inhibition of beta-hematin formation after 16 hrs at pH 5.2 by microplate reader,Confirmatory,22512909.0,
981,660169,2,2,,103401109,441074,Active,,,23.0,IC50,Inhibition of beta-hematin formation after 16 hrs at pH 5.6 by microplate reader,Confirmatory,22512909.0,
982,660170,1,4,,103401109,441074,Active,,,0.018000000000000002,IC50,Antimalarial activity against chloroquine sensitive Plasmodium falciparum HB3 after 72 hrs by SYBP Green I dye staining,Confirmatory,22512909.0,
983,660171,1,3,,103401109,441074,Active,,,0.09,IC50,Antimalarial activity against chloroquine resistant Plasmodium falciparum Dd2 after 72 hrs by SYBP Green I dye staining,Confirmatory,22512909.0,
984,669779,1,8,,103401109,441074,Unspecified,60392839.0,,,,Inhibition of norA-mediated ethidium bromide efflux in Staphylococcus aureus SA-1199B harboring grlA A116E mutant at 50 uM after 5 mins by fluorometric analysis,Other,24900460.0,
985,669781,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-4 M preincubated for 10 mins measured after 20 mins by FACS analysis,Other,24900460.0,
986,678712,1,8,,103401109,441074,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
987,678713,1,8,,103401109,441074,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
988,678714,1,8,,103401109,441074,Unspecified,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
989,678715,1,8,,103401109,441074,Inconclusive,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
990,678716,1,8,,103401109,441074,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
991,678717,1,8,,103401109,441074,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
992,678718,1,5,,103401109,441074,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
993,678722,1,5,,103401109,441074,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
994,678752,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in spleen concentration in mdr1a(-/-) mouse,Other,9927403.0,
995,678755,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in small intestine concentration in mdr1a(-/-) mouse,Other,9927403.0,
996,678759,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in plasma concentration in mdr1a(-/-) mouse,Other,9927403.0,
997,678763,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in lung concentration in mdr1a(-/-) mouse,Other,9927403.0,
998,678765,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in liver concentration in mdr1a(-/-) mouse,Other,9927403.0,
999,678769,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in kidney concentration in mdr1a(-/-) mouse,Other,9927403.0,
1000,678811,1,8,,103401109,441074,Unspecified,146345508.0,6583.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,10215651.0,
1001,678825,1,8,,103401109,441074,Unspecified,1171882.0,6579.0,,,TP_TRANSPORTER: inhibition of Rocuronium uptake in Xenopus laevis oocytes,Other,11408531.0,
1002,678834,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12948010.0,
1003,678903,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,9353372.0,
1004,679080,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Quinidine at a concentration of 1 uM in MDR1-expressing MDCK cells,Other,12948019.0,
1005,679081,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Quinidine at a concentration of 1 uM in Caco-2 cells,Other,12948019.0,
1006,679154,3,6,,103401109,441074,Unspecified,313104181.0,6580.0,23.4,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells,Confirmatory,10027858.0,
1007,679155,1,7,,103401109,441074,Unspecified,313104181.0,6580.0,,,TP_TRANSPORTER: inhibition of TBuMA uptake in Xenopus laevis oocytes,Other,11408531.0,
1008,679241,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,9927403.0,
1009,679270,1,9,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (apical to basal) of Quinidine at a concentration of 50 nM in MDR1-expressing LLC-PK1 cells,Other,11785684.0,
1010,679315,2,7,,103401109,441074,Unspecified,81872095.0,24904.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,8898084.0,
1011,679319,1,7,,103401109,441074,Unspecified,81872095.0,24904.0,,,TP_TRANSPORTER: inhibition of TBuMA uptake in Xenopus laevis oocytes,Other,11408531.0,
1012,679340,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,11496955.0,
1013,679470,2,8,,103401109,441074,Unspecified,238054374.0,5243.0,18.2,Km,TP_TRANSPORTER: ATP hydrolysis in membranes from P-gp expressing insect cells,Confirmatory,11504828.0,
1014,679493,2,7,,103401109,441074,Unspecified,3914190.0,170698.0,120.0,Ki,TP_TRANSPORTER: inhibition of Digoxin uptake in Oatp2-expressing LLC-PK1 cells,Confirmatory,11883641.0,
1015,679607,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1uM, Quinidine: 20 uM) in MDR1-expressing LLC-PK1 cells",Other,1359120.0,
1016,679787,2,7,,103401109,441074,Unspecified,81911503.0,,5.0,Km,TP_TRANSPORTER: uptake in rat canalicular membrane vesicle,Confirmatory,7909523.0,
1017,679922,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Saquinavir transepithelial transport (basal to apical) (Saquinavir: 5 uM, Quinidine: 5 uM) in Caco-2 cells",Other,9435299.0,
1018,680010,1,8,,103401109,441074,Unspecified,1171882.0,6579.0,,,"TP_TRANSPORTER: inhibition of Fexofenadine uptake (Fexofenadine: 2 uM, Quinidine: 100 uM) in Xenopus laevis oocytes",Other,10421612.0,
1019,680280,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Quinidine: 20 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
1020,680393,1,8,,103401109,441074,Unspecified,146345508.0,6583.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Quinidine: 1000 uM) in Xenopus laevis oocytes",Other,10215651.0,
1021,680476,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Nelfinavir transepithelial transport (basal to apical) (Nelfinavir: 5 uM, Quinidine: 5 uM) in Caco-2 cells",Other,9435299.0,
1022,680481,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 uM, Quinidine: 50 uM) in MDR1-expressing LLC-PK1 cells",Other,9262363.0,
1023,680491,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Indinavir transepithelial transport (basal to apical) (Indinavir: 5 uM, Quinidine: 5 uM) in Caco-2 cells",Other,9435299.0,
1024,680531,1,7,,103401109,441074,Unspecified,8928277.0,20520.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Quinidine: 500 uM) in OCTN2-expressing HEK293 cells",Other,11160873.0,
1025,680759,1,8,,103401109,441074,Unspecified,12643959.0,10599.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.004 uM, Quinidine: 500 uM) in Xenopus laevis oocytes",Other,12906759.0,
1026,680794,1,8,,103401109,441074,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical)(Quinidine: 15 uM) in MRP2-expressing MDCK cells,Other,12134946.0,
1027,681047,1,7,,103401109,441074,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Quinidine: 5 uM) in Xenopus laevis oocytes",Other,11306713.0,
1028,681117,3,6,,103401109,441074,Unspecified,313104181.0,6580.0,,IC50,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,12606755.0,
1029,681118,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
1030,681119,3,6,,103401109,441074,Unspecified,239938877.0,18671.0,13.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1031,681120,1,8,,103401109,441074,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells,Other,12699389.0,
1032,681122,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,5.6,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1033,681126,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,33.9,IC50,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1034,681127,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,1.0,IC50,TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1035,681128,3,6,,103401109,441074,Unspecified,126927.0,18669.0,10.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1036,681131,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,18.8,IC50,TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1037,681139,3,6,,103401109,441074,Unspecified,262527527.0,8647.0,,IC50,TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP),Confirmatory,12739759.0,
1038,681144,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,33.8,IC50,TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells,Confirmatory,12649369.0,
1039,681146,3,6,,103401109,441074,Unspecified,313104181.0,6580.0,17.5,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,9655880.0,
1040,681158,3,6,,103401109,441074,Unspecified,81872789.0,29503.0,14.6,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes,Confirmatory,11502595.0,
1041,681159,3,6,,103401109,441074,Unspecified,81872095.0,24904.0,12.7,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes,Confirmatory,11502595.0,
1042,681164,2,8,,103401109,441074,Unspecified,238054374.0,5243.0,5.42,Km,TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells,Confirmatory,11785684.0,
1043,681169,2,7,,103401109,441074,Unspecified,8928257.0,6584.0,,Km,TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells,Confirmatory,10525100.0,
1044,681356,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,8.59,Ki,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells,Confirmatory,12134945.0,
1045,681358,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,2.2,IC50,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells,Confirmatory,10820137.0,
1046,681376,3,6,,103401109,441074,Unspecified,81872095.0,24904.0,6.0,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT1-expressing HEK293 cells,Confirmatory,8878062.0,
1047,681383,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,1.5,Ki,TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,11405287.0,
1048,681573,2,7,,103401109,441074,Unspecified,81872095.0,24904.0,2.2,Km,TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes,Confirmatory,8955087.0,
1049,681574,3,6,,103401109,441074,Unspecified,81872095.0,24904.0,14.6,Ki,TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT1-expressing MDCK cells,Confirmatory,9808712.0,
1050,681590,3,6,,103401109,441074,Unspecified,81872789.0,29503.0,19.1,Ki,TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT2-expressing MDCK cells,Confirmatory,9808712.0,
1051,681611,3,6,,103401109,441074,Unspecified,238054374.0,5243.0,0.43,Ki,TP_TRANSPORTER: transepithelial transport of digoxin (basal to apical) in Caco-2 cells,Confirmatory,12636153.0,
1052,681937,1,7,,103401109,441074,Unspecified,313104181.0,6580.0,,,TP_TRANSPORTER: inhibition of Tetraethyl ammonium uptake (Quinidine:100 uM) in OCT1-expressing HeLa cells,Other,15716364.0,
1053,681951,1,7,,103401109,441074,Unspecified,313104181.0,6580.0,,,"TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Quinidine: 1000 uM) in Xenopus laevis oocytes",Other,9187257.0,
1054,681971,1,7,,103401109,441074,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Quinidine: 1000 uM) in OCT2A-expressing HEK293 cells",Other,12089365.0,
1055,681972,1,7,,103401109,441074,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Quinidine: 1000 uM) in OCT2-expressing HEK293 cells",Other,12089365.0,
1056,682009,1,8,,103401109,441074,Unspecified,189046191.0,20517.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM, Quinidine: 1000 uM) in Oct1-expressing BALB/3T3 cells",Other,11060354.0,
1057,682025,1,8,,103401109,441074,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,9927403.0,
1058,682052,2,7,,103401109,441074,Unspecified,1171883.0,50572.0,9.27,Ki,TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing LLC-PK1 cells,Confirmatory,11883641.0,
1059,682295,1,7,,103401109,441074,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Quinidine: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
1060,686940,1,1,,56320932,441074,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1061,686964,1,1,,56320932,441074,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1062,686970,1,2,,56320932,441074,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1063,686971,1,2,,56320932,441074,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1064,686977,2,1,,49699334,441074,Inconclusive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1065,686978,1,1,,56320932,441074,Inconclusive,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1066,686979,1,1,,56320932,441074,Inconclusive,79154014.0,55775.0,12.9953,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1067,686992,2,1,,56320932,441074,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1068,686996,1,1,,56320932,441074,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1069,687014,1,1,,56320932,441074,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1070,687016,1,1,,56320932,441074,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1071,693225,1,7,,103401109,441074,Inconclusive,130912.0,5621.0,,,Binding affinity to truncated human PrP 121-231 at 50 uM by surface plasmon resonance method,Other,21531054.0,
1072,693226,1,2,,103401109,441074,Unspecified,,,,,Effective permeability of the compound at pH 7.4 at 30 to 50 uM by PAMPA assay,Other,21531054.0,
1073,697829,4,5,,103401109,441074,Active,21362409.0,100033901.0,7.37,IC50,Inhibition of horse BChE by Ellman's method,Confirmatory,23062825.0,
1074,697830,4,5,,103401109,441074,Active,116353.0,590.0,1.23,IC50,Inhibition of human BChE by Ellman's method,Confirmatory,23062825.0,
1075,697831,4,5,,103401109,441074,Inactive,14916521.0,,,IC50,Inhibition of electric eel AChE by Ellman's method,Confirmatory,23062825.0,
1076,699539,1,7,,103401109,441074,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1077,699540,1,7,,103401109,441074,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1078,699541,1,7,,103401109,441074,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1079,720504,1,1,,56320932,441074,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1080,720508,1,1,,56320932,441074,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1081,720509,1,1,,56320932,441074,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1082,720511,1,1,,56320932,441074,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1083,720542,1,2,,56320932,441074,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1084,720543,1,1,,56320932,441074,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1085,720551,1,2,,56320932,441074,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1086,720553,1,2,,56320932,441074,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1087,720554,1,3,,121362609,441074,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
1088,720579,2,1,,56320932,441074,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1089,720580,1,1,,56320932,441074,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1090,720582,1,1,,56320932,441074,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1091,720596,1,1,,56320932,441074,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1092,720636,1,1,,17389531,441074,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1093,720647,1,2,,56320932,441074,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1094,720648,1,1,,56320932,441074,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1095,720652,1,1,,17389531,441074,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1096,720653,1,1,,17389531,441074,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1097,720659,1,1,,17389531,441074,Active,325495557.0,8856.0,31.6228,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1098,720700,1,4,,56320932,441074,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1099,720702,1,1,,56320932,441074,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1100,720704,1,4,,56320932,441074,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1101,720707,1,2,,56320932,441074,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1102,720708,1,2,,56320932,441074,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1103,720709,1,2,,56320932,441074,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1104,720711,1,2,,56320932,441074,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1105,721753,1,6,,103401109,441074,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
1106,721754,2,5,,103401109,441074,Active,74731723.0,55244.0,11.2,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
1107,732420,1,3,,103401109,441074,Unspecified,,,,,Efflux ratio of permeability from basolateral to apical side over apical to basolateral in pig LLC-PK1 cells overexpressing human MDR1 relative to efflux ratio in parental cell line,Other,24900570.0,
1108,743126,1,1,,56320932,441074,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1109,743238,1,1,,56320932,441074,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1110,743247,1,2,,56320932,441074,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1111,743255,1,1,,56320932,441074,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1112,743266,1,2,,56320932,441074,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1113,743268,1,1,,172080601,441074,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
1114,743269,1,1,,56320932,441074,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1115,743269,1,1,,56320932,441074,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1116,743270,1,1,,172080601,441074,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
1117,743271,1,1,,172080601,441074,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
1118,743272,1,1,,172080601,441074,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
1119,743279,1,2,,56320932,441074,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1120,743288,1,1,,17389531,441074,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1121,743292,1,1,,17389531,441074,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1122,743397,1,1,,56320932,441074,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1123,743398,1,1,,56320932,441074,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1124,764197,1,1,,103401109,441074,Unspecified,,,,,"Selectivity index, ratio of IC50 for human WI38 cells to IC50 for erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D7",Other,23816880.0,
1125,764198,1,1,,103401109,441074,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes",Other,23816880.0,
1126,764199,1,1,,103401109,441074,Unspecified,,,,,Antiplasmodial activity against erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite LDH activity by three-fold serial dilution method,Other,23816880.0,
1127,764200,1,1,,103401109,441074,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes assessed as parasite LDH activity by three-fold serial dilution method,Other,23816880.0,
1128,764201,1,1,,103401109,441074,Unspecified,,,,,"Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream form",Other,23816880.0,
1129,764202,1,1,,103401109,441074,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream form assessed as parasite LDH activity by three-fold serial dilution method,Other,23816880.0,
1130,764203,1,1,,103401109,441074,Unspecified,,,,,Cytotoxicity against human WI38 cells by MTT assay,Other,23816880.0,
1131,773778,1,5,,103401109,441074,Active,84028191.0,1565.0,0.002,IC50,"Inhibition of human recombinant microsomal CYP2D6 using {3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin} as substrate assessed as remaining activity at 10 uM after 30 mins by spectrofluorimetric analysis relative to control",Confirmatory,24050112.0,
1132,774144,1,5,,103401109,441074,Unspecified,116241312.0,1576.0,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-hydroxymidazolam at 10 uM after 10 mins relative to control,Other,24079662.0,
1133,774147,1,5,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol hydroxylation to 4'-hydroxybufuralol at 10 uM after 10 mins relative to control,Other,24079662.0,
1134,774148,1,5,,103401109,441074,Unspecified,117144.0,1544.0,,,Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin demethylation to acetaminophen at 10 uM after 10 mins relative to control,Other,24079662.0,
1135,774150,1,5,,103401109,441074,Unspecified,6686268.0,1559.0,,,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Other,24079662.0,
1136,781328,1,2,,103401109,441074,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
1137,895599,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/6,Other,,
1138,895600,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/6,Other,,
1139,895601,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/6,Other,,
1140,895602,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/6,Other,,
1141,895603,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/6,Other,,
1142,895604,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/6,Other,,
1143,895605,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/6,Other,,
1144,895606,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/7,Other,,
1145,895607,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/7,Other,,
1146,895608,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/7,Other,,
1147,895609,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/7,Other,,
1148,895610,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/7,Other,,
1149,895611,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/7,Other,,
1150,895612,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/7,Other,,
1151,895613,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/7,Other,,
1152,895614,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/7,Other,,
1153,895615,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/7,Other,,
1154,895616,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/7,Other,,
1155,895617,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/7,Other,,
1156,895618,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/7,Other,,
1157,895619,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/7,Other,,
1158,895620,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/7,Other,,
1159,895621,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/7,Other,,
1160,895622,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/7,Other,,
1161,895623,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/7,Other,,
1162,895624,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/7,Other,,
1163,896307,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/7,Other,,
1164,896308,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/7,Other,,
1165,896309,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/8,Other,,
1166,896310,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/8,Other,,
1167,896311,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/8,Other,,
1168,896312,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/8,Other,,
1169,896313,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/8,Other,,
1170,896314,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/8,Other,,
1171,896315,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/8,Other,,
1172,896316,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/8,Other,,
1173,896317,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/8,Other,,
1174,896318,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/8,Other,,
1175,896319,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/8,Other,,
1176,896320,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/8,Other,,
1177,896321,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/8,Other,,
1178,896322,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/8,Other,,
1179,896323,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/8,Other,,
1180,896324,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/8,Other,,
1181,896325,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/8,Other,,
1182,896326,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/8,Other,,
1183,896327,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/8,Other,,
1184,896363,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/15,Other,,
1185,896364,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/15,Other,,
1186,896365,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/15,Other,,
1187,896366,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/15,Other,,
1188,896367,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/15,Other,,
1189,896368,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/15,Other,,
1190,896369,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/15,Other,,
1191,896370,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/15,Other,,
1192,896371,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/16,Other,,
1193,896372,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/16,Other,,
1194,896373,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/16,Other,,
1195,896374,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/16,Other,,
1196,896375,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/16,Other,,
1197,896376,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/16,Other,,
1198,896377,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/16,Other,,
1199,896378,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/16,Other,,
1200,896379,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/16,Other,,
1201,896380,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/16,Other,,
1202,896381,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/16,Other,,
1203,896382,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/16,Other,,
1204,896383,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/16,Other,,
1205,896384,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/16,Other,,
1206,896385,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/16,Other,,
1207,896386,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/16,Other,,
1208,896387,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/16,Other,,
1209,896388,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/16,Other,,
1210,896389,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/16,Other,,
1211,896390,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/16,Other,,
1212,896391,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/16,Other,,
1213,897025,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/11,Other,,
1214,897026,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/11,Other,,
1215,897027,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/11,Other,,
1216,897028,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/11,Other,,
1217,897029,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/12,Other,,
1218,897712,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/12,Other,,
1219,897713,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/12,Other,,
1220,897714,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/12,Other,,
1221,897715,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/12,Other,,
1222,897716,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/12,Other,,
1223,897717,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/12,Other,,
1224,897718,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/12,Other,,
1225,897719,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/12,Other,,
1226,897720,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/12,Other,,
1227,897721,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/12,Other,,
1228,897722,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/12,Other,,
1229,897723,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/12,Other,,
1230,897724,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/12,Other,,
1231,897725,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/12,Other,,
1232,897726,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/12,Other,,
1233,897727,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/12,Other,,
1234,897728,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/12,Other,,
1235,897729,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/12,Other,,
1236,897730,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/12,Other,,
1237,897731,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/12,Other,,
1238,897732,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/13,Other,,
1239,897733,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/13,Other,,
1240,897734,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/13,Other,,
1241,897735,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/13,Other,,
1242,897736,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/13,Other,,
1243,897737,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/13,Other,,
1244,897738,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/13,Other,,
1245,897739,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/13,Other,,
1246,897740,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/13,Other,,
1247,897741,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/13,Other,,
1248,897742,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/13,Other,,
1249,897743,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/13,Other,,
1250,897744,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/13,Other,,
1251,897745,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/13,Other,,
1252,897746,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/13,Other,,
1253,897747,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/13,Other,,
1254,897748,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/13,Other,,
1255,897749,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/13,Other,,
1256,897750,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/13,Other,,
1257,897751,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/13,Other,,
1258,897752,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/13,Other,,
1259,897753,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/14,Other,,
1260,897754,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/14,Other,,
1261,898511,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/8,Other,,
1262,898512,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/8,Other,,
1263,898513,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/9,Other,,
1264,898514,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/9,Other,,
1265,898515,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/9,Other,,
1266,898516,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/9,Other,,
1267,898517,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/9,Other,,
1268,898518,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/9,Other,,
1269,898519,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/9,Other,,
1270,898520,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/9,Other,,
1271,898521,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/9,Other,,
1272,898522,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/9,Other,,
1273,898523,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/9,Other,,
1274,898524,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/9,Other,,
1275,898525,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/9,Other,,
1276,898526,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/9,Other,,
1277,898527,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/9,Other,,
1278,899211,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/9,Other,,
1279,899212,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/9,Other,,
1280,899213,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/9,Other,,
1281,899214,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/9,Other,,
1282,899215,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/9,Other,,
1283,899216,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/9,Other,,
1284,899217,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/10,Other,,
1285,899218,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/10,Other,,
1286,899219,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/10,Other,,
1287,899220,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/10,Other,,
1288,899221,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/10,Other,,
1289,899222,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/10,Other,,
1290,899223,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/10,Other,,
1291,899224,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/10,Other,,
1292,899225,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/10,Other,,
1293,899226,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/10,Other,,
1294,899227,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/10,Other,,
1295,899228,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/10,Other,,
1296,899229,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/10,Other,,
1297,899230,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/10,Other,,
1298,899231,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/10,Other,,
1299,899232,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/10,Other,,
1300,899233,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/10,Other,,
1301,899234,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/10,Other,,
1302,899235,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/10,Other,,
1303,899236,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/10,Other,,
1304,899237,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/10,Other,,
1305,899238,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/11,Other,,
1306,899239,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/11,Other,,
1307,899240,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/11,Other,,
1308,899859,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/5,Other,,
1309,899860,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/5,Other,,
1310,899861,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/5,Other,,
1311,899862,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/5,Other,,
1312,899863,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/5,Other,,
1313,899864,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/5,Other,,
1314,899865,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/5,Other,,
1315,899866,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/5,Other,,
1316,899867,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/5,Other,,
1317,899868,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/5,Other,,
1318,899869,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/5,Other,,
1319,899870,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/5,Other,,
1320,899871,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/5,Other,,
1321,899872,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/5,Other,,
1322,899873,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/5,Other,,
1323,899874,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/5,Other,,
1324,899875,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/5,Other,,
1325,899876,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/5,Other,,
1326,899877,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/5,Other,,
1327,899878,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/5,Other,,
1328,899879,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/5,Other,,
1329,899880,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/6,Other,,
1330,899881,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/6,Other,,
1331,899882,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/6,Other,,
1332,899883,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/6,Other,,
1333,899884,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/6,Other,,
1334,899885,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/6,Other,,
1335,899886,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/6,Other,,
1336,899887,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/6,Other,,
1337,900570,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/6,Other,,
1338,900571,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/6,Other,,
1339,900572,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/6,Other,,
1340,900573,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/6,Other,,
1341,900574,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/6,Other,,
1342,900575,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/6,Other,,
1343,900576,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/6,Other,,
1344,900577,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/6,Other,,
1345,900578,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/6,Other,,
1346,900579,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/6,Other,,
1347,900580,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/6,Other,,
1348,900581,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/6,Other,,
1349,900582,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/7,Other,,
1350,900583,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/7,Other,,
1351,900584,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/7,Other,,
1352,900585,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/7,Other,,
1353,900586,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/7,Other,,
1354,900613,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/6,Other,,
1355,900619,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/14,Other,,
1356,900620,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/14,Other,,
1357,900621,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/14,Other,,
1358,900622,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/14,Other,,
1359,900623,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/14,Other,,
1360,900624,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/14,Other,,
1361,900625,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/14,Other,,
1362,900626,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/14,Other,,
1363,900627,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/14,Other,,
1364,900628,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/14,Other,,
1365,900629,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/14,Other,,
1366,900630,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/14,Other,,
1367,900631,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/14,Other,,
1368,900632,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/14,Other,,
1369,900633,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/14,Other,,
1370,900634,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/14,Other,,
1371,900635,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/14,Other,,
1372,900636,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/14,Other,,
1373,900637,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/14,Other,,
1374,900638,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/15,Other,,
1375,900639,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/15,Other,,
1376,900640,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/15,Other,,
1377,900641,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/15,Other,,
1378,900642,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/15,Other,,
1379,900643,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/15,Other,,
1380,900644,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/15,Other,,
1381,900645,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/15,Other,,
1382,900646,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/15,Other,,
1383,900647,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/15,Other,,
1384,900648,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/15,Other,,
1385,900649,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/15,Other,,
1386,900650,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/15,Other,,
1387,900651,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/15,Other,,
1388,900652,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/15,Other,,
1389,900653,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/15,Other,,
1390,900654,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/15,Other,,
1391,900655,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/15,Other,,
1392,900656,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/15,Other,,
1393,900657,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/15,Other,,
1394,900658,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/15,Other,,
1395,900659,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/16,Other,,
1396,900660,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/16,Other,,
1397,900661,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/16,Other,,
1398,901340,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/16,Other,,
1399,901341,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/16,Other,,
1400,901342,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/16,Other,,
1401,901343,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/16,Other,,
1402,901344,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/16,Other,,
1403,901423,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/11,Other,,
1404,901424,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/11,Other,,
1405,901425,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/11,Other,,
1406,901426,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/11,Other,,
1407,901427,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/11,Other,,
1408,901428,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/11,Other,,
1409,901429,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/11,Other,,
1410,902115,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/11,Other,,
1411,902116,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/11,Other,,
1412,902117,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/11,Other,,
1413,902118,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/11,Other,,
1414,902119,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/11,Other,,
1415,902120,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/11,Other,,
1416,902121,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/11,Other,,
1417,902122,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/11,Other,,
1418,902123,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/11,Other,,
1419,902124,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/11,Other,,
1420,902125,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/11,Other,,
1421,902126,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/12,Other,,
1422,902127,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/12,Other,,
1423,902128,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/12,Other,,
1424,902129,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/12,Other,,
1425,902130,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/12,Other,,
1426,902131,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/12,Other,,
1427,902132,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/12,Other,,
1428,902133,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/12,Other,,
1429,902134,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/12,Other,,
1430,902135,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/12,Other,,
1431,902136,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/12,Other,,
1432,902137,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/12,Other,,
1433,902138,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/12,Other,,
1434,902139,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/12,Other,,
1435,902140,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/12,Other,,
1436,902141,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/12,Other,,
1437,902142,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/12,Other,,
1438,902143,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/12,Other,,
1439,902144,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/12,Other,,
1440,902145,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/12,Other,,
1441,902146,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/12,Other,,
1442,902147,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/13,Other,,
1443,902148,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/13,Other,,
1444,902149,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/13,Other,,
1445,902150,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/13,Other,,
1446,902151,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/13,Other,,
1447,902152,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/13,Other,,
1448,902153,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/13,Other,,
1449,902154,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/13,Other,,
1450,902769,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/7,Other,,
1451,902770,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/7,Other,,
1452,902771,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/7,Other,,
1453,902772,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/7,Other,,
1454,902773,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/7,Other,,
1455,902774,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/7,Other,,
1456,902775,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/7,Other,,
1457,902776,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/7,Other,,
1458,902777,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/7,Other,,
1459,902778,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/7,Other,,
1460,902779,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/7,Other,,
1461,902780,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/7,Other,,
1462,902781,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/7,Other,,
1463,902782,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/7,Other,,
1464,902783,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/7,Other,,
1465,902784,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/7,Other,,
1466,902785,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/8,Other,,
1467,902786,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/8,Other,,
1468,902787,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/8,Other,,
1469,902788,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/8,Other,,
1470,902789,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/8,Other,,
1471,902790,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/8,Other,,
1472,902791,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/8,Other,,
1473,902792,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/8,Other,,
1474,903474,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/8,Other,,
1475,903475,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/8,Other,,
1476,903476,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/8,Other,,
1477,903477,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/8,Other,,
1478,903478,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/8,Other,,
1479,903479,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/8,Other,,
1480,903480,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/8,Other,,
1481,903481,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/8,Other,,
1482,903482,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/8,Other,,
1483,903483,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/8,Other,,
1484,903484,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/8,Other,,
1485,903485,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/8,Other,,
1486,903486,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/8,Other,,
1487,903487,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/9,Other,,
1488,903488,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/9,Other,,
1489,903489,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/9,Other,,
1490,903490,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/9,Other,,
1491,903491,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/9,Other,,
1492,903492,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/9,Other,,
1493,903493,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/9,Other,,
1494,903494,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/9,Other,,
1495,903495,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/9,Other,,
1496,903496,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/9,Other,,
1497,903497,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/9,Other,,
1498,903532,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/16,Other,,
1499,903533,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/16,Other,,
1500,903534,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/16,Other,,
1501,903535,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/16,Other,,
1502,903536,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/16,Other,,
1503,903537,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/16,Other,,
1504,903538,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/16,Other,,
1505,903539,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/16,Other,,
1506,903540,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/16,Other,,
1507,903541,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/16,Other,,
1508,903542,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/16,Other,,
1509,903543,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/16,Other,,
1510,903544,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/16,Other,,
1511,903545,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/5,Other,,
1512,903546,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/5,Other,,
1513,903547,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/5,Other,,
1514,903548,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/5,Other,,
1515,903549,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/5,Other,,
1516,903550,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/5,Other,,
1517,903551,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/5,Other,,
1518,903552,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/5,Other,,
1519,903553,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/5,Other,,
1520,903554,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/5,Other,,
1521,903555,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/5,Other,,
1522,903556,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/5,Other,,
1523,903557,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/5,Other,,
1524,903558,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/5,Other,,
1525,903559,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/5,Other,,
1526,903560,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/5,Other,,
1527,903561,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/5,Other,,
1528,903562,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/5,Other,,
1529,903563,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/5,Other,,
1530,903564,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/5,Other,,
1531,903565,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/5,Other,,
1532,904246,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/6,Other,,
1533,904247,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/6,Other,,
1534,904248,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/6,Other,,
1535,904249,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/6,Other,,
1536,904250,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/6,Other,,
1537,904251,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/6,Other,,
1538,904252,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/6,Other,,
1539,904253,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/6,Other,,
1540,904254,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/6,Other,,
1541,904255,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/6,Other,,
1542,904256,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/6,Other,,
1543,904257,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/6,Other,,
1544,904258,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/6,Other,,
1545,904259,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/6,Other,,
1546,905022,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/13,Other,,
1547,905023,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/13,Other,,
1548,905024,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/13,Other,,
1549,905025,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/13,Other,,
1550,905026,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/13,Other,,
1551,905027,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/13,Other,,
1552,905028,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/13,Other,,
1553,905029,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/13,Other,,
1554,905030,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/13,Other,,
1555,905031,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/13,Other,,
1556,905032,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/13,Other,,
1557,905033,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/13,Other,,
1558,905034,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/13,Other,,
1559,905035,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/14,Other,,
1560,905036,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/14,Other,,
1561,905037,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/14,Other,,
1562,905038,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/14,Other,,
1563,905039,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/14,Other,,
1564,905040,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/14,Other,,
1565,905041,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/14,Other,,
1566,905042,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/14,Other,,
1567,905043,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/14,Other,,
1568,905044,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/14,Other,,
1569,905045,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/14,Other,,
1570,905046,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/14,Other,,
1571,905047,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/14,Other,,
1572,905048,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 350/14,Other,,
1573,905049,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 350/14,Other,,
1574,905050,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 350/14,Other,,
1575,905051,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 350/14,Other,,
1576,905052,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 350/14,Other,,
1577,905053,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 350/14,Other,,
1578,905054,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 350/14,Other,,
1579,905055,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 350/14,Other,,
1580,905056,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 350/15,Other,,
1581,905057,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 350/15,Other,,
1582,905058,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 350/15,Other,,
1583,905059,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 350/15,Other,,
1584,905060,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 350/15,Other,,
1585,905061,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 350/15,Other,,
1586,905062,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 350/15,Other,,
1587,905063,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 350/15,Other,,
1588,905064,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 350/15,Other,,
1589,905682,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/9,Other,,
1590,905683,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/9,Other,,
1591,905684,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/9,Other,,
1592,905685,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/9,Other,,
1593,905686,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/9,Other,,
1594,905687,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/9,Other,,
1595,905688,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/9,Other,,
1596,905689,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/9,Other,,
1597,905690,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/9,Other,,
1598,905691,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/9,Other,,
1599,905692,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/10,Other,,
1600,905693,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/10,Other,,
1601,905694,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/10,Other,,
1602,905695,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/10,Other,,
1603,905696,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/10,Other,,
1604,905743,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 350/15,Other,,
1605,905744,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 350/15,Other,,
1606,905745,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 350/15,Other,,
1607,905746,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 350/15,Other,,
1608,906379,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/10,Other,,
1609,906380,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/10,Other,,
1610,906381,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/10,Other,,
1611,906382,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/10,Other,,
1612,906383,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/10,Other,,
1613,906384,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/10,Other,,
1614,906385,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/10,Other,,
1615,906386,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/10,Other,,
1616,906387,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/10,Other,,
1617,906388,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/10,Other,,
1618,906389,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/10,Other,,
1619,906390,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/10,Other,,
1620,906391,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 349/10,Other,,
1621,906392,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 349/10,Other,,
1622,906393,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 349/10,Other,,
1623,906394,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 349/10,Other,,
1624,906395,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 349/11,Other,,
1625,906396,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 349/11,Other,,
1626,906397,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 349/11,Other,,
1627,906398,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 349/11,Other,,
1628,906399,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 349/11,Other,,
1629,906400,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 349/11,Other,,
1630,906401,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 349/11,Other,,
1631,906402,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 349/11,Other,,
1632,906403,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 349/11,Other,,
1633,906404,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 349/11,Other,,
1634,906405,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 349/11,Other,,
1635,906406,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 349/11,Other,,
1636,906407,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 349/11,Other,,
1637,906408,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 349/11,Other,,
1638,906409,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 349/11,Other,,
1639,906410,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 349/11,Other,,
1640,906411,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 349/11,Other,,
1641,1035878,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/13,Other,,
1642,1035879,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/13,Other,,
1643,1035880,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/13,Other,,
1644,1035881,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/13,Other,,
1645,1035882,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/13,Other,,
1646,1035883,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/14,Other,,
1647,1035884,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/14,Other,,
1648,1035885,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/14,Other,,
1649,1035886,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/14,Other,,
1650,1035887,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/14,Other,,
1651,1035888,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/15,Other,,
1652,1035889,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/15,Other,,
1653,1035890,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/15,Other,,
1654,1035891,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/15,Other,,
1655,1035892,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/15,Other,,
1656,1035893,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/16,Other,,
1657,1035894,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/16,Other,,
1658,1035895,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/16,Other,,
1659,1035896,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/16,Other,,
1660,1035897,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/16,Other,,
1661,1035898,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/5,Other,,
1662,1035899,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/5,Other,,
1663,1035900,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/5,Other,,
1664,1035901,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/5,Other,,
1665,1035902,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/5,Other,,
1666,1035903,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/6,Other,,
1667,1035904,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/6,Other,,
1668,1035905,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/6,Other,,
1669,1035906,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/6,Other,,
1670,1035907,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/6,Other,,
1671,1035908,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/7,Other,,
1672,1035909,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/7,Other,,
1673,1035910,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/7,Other,,
1674,1035911,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/7,Other,,
1675,1035912,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/7,Other,,
1676,1035913,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/8,Other,,
1677,1035914,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/8,Other,,
1678,1035915,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/8,Other,,
1679,1035916,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/8,Other,,
1680,1035917,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/8,Other,,
1681,1035918,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/9,Other,,
1682,1035919,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/9,Other,,
1683,1036585,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/9,Other,,
1684,1036586,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/9,Other,,
1685,1036587,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/9,Other,,
1686,1036588,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/10,Other,,
1687,1036589,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/10,Other,,
1688,1038734,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/10,Other,,
1689,1038735,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/10,Other,,
1690,1038736,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/10,Other,,
1691,1038737,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/11,Other,,
1692,1038738,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/11,Other,,
1693,1038739,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/11,Other,,
1694,1038740,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/11,Other,,
1695,1038741,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/11,Other,,
1696,1038742,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/12,Other,,
1697,1038743,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/12,Other,,
1698,1038744,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/12,Other,,
1699,1038745,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/12,Other,,
1700,1038746,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/12,Other,,
1701,1038747,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/13,Other,,
1702,1038748,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/13,Other,,
1703,1038749,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/13,Other,,
1704,1038750,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/13,Other,,
1705,1038751,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/13,Other,,
1706,1038752,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/14,Other,,
1707,1038753,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/14,Other,,
1708,1038754,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/14,Other,,
1709,1038755,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/14,Other,,
1710,1038756,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/14,Other,,
1711,1038757,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/15,Other,,
1712,1038758,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/15,Other,,
1713,1038759,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/15,Other,,
1714,1038760,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/15,Other,,
1715,1038761,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/15,Other,,
1716,1038762,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 350/16,Other,,
1717,1038763,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 350/16,Other,,
1718,1038764,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 350/16,Other,,
1719,1038765,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 350/16,Other,,
1720,1038766,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 350/16,Other,,
1721,1044380,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/5,Other,,
1722,1044381,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/5,Other,,
1723,1044382,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/5,Other,,
1724,1044383,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/5,Other,,
1725,1044384,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/5,Other,,
1726,1044385,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/6,Other,,
1727,1044386,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/6,Other,,
1728,1044387,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/6,Other,,
1729,1044388,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/6,Other,,
1730,1044389,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/6,Other,,
1731,1044390,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/7,Other,,
1732,1044391,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/7,Other,,
1733,1044392,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/7,Other,,
1734,1044393,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/7,Other,,
1735,1044394,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/7,Other,,
1736,1044395,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/8,Other,,
1737,1044396,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/8,Other,,
1738,1044397,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/8,Other,,
1739,1044398,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/8,Other,,
1740,1044399,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/8,Other,,
1741,1044400,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/9,Other,,
1742,1044401,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/9,Other,,
1743,1044402,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/9,Other,,
1744,1044403,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/9,Other,,
1745,1044404,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/9,Other,,
1746,1044405,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/10,Other,,
1747,1044406,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/10,Other,,
1748,1044407,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/10,Other,,
1749,1044408,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/10,Other,,
1750,1044409,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/10,Other,,
1751,1044410,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/11,Other,,
1752,1044411,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/11,Other,,
1753,1044412,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/11,Other,,
1754,1044413,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/11,Other,,
1755,1044414,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/11,Other,,
1756,1044415,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 349/12,Other,,
1757,1044416,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 349/12,Other,,
1758,1044417,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 349/12,Other,,
1759,1044418,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 349/12,Other,,
1760,1044419,1,2,,103401109,441074,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 349/12,Other,,
1761,1053197,1,1,,56320932,441074,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1762,1072933,1,4,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6 (unknown origin) at 10 uM relative to control,Other,24900814.0,
1763,1079931,1,1,,103401109,441074,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1764,1079932,1,1,,103401109,441074,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1765,1079933,1,1,,103401109,441074,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1766,1079934,1,1,,103401109,441074,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1767,1079935,1,1,,103401109,441074,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1768,1079936,1,1,,103401109,441074,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1769,1079937,1,1,,103401109,441074,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1770,1079938,1,1,,103401109,441074,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1771,1079939,1,1,,103401109,441074,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1772,1079940,1,1,,103401109,441074,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1773,1079941,1,1,,103401109,441074,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1774,1079942,1,1,,103401109,441074,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1775,1079943,1,1,,103401109,441074,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1776,1079944,1,1,,103401109,441074,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1777,1079945,1,1,,103401109,441074,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1778,1079946,1,1,,103401109,441074,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1779,1079947,1,1,,103401109,441074,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1780,1079948,1,1,,103401109,441074,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1781,1079949,1,1,,103401109,441074,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1782,1093921,1,2,,103401109,441074,Active,,,0.051,IC50,Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as incorporation of [3H]hypoxanthine after 48 hr microdilution method,Confirmatory,,
1783,1093922,1,2,,103401109,441074,Active,,,0.021,IC50,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hr microdilution method,Confirmatory,,
1784,1093923,1,2,,103401109,441074,Active,,,24.0,IC50,Inhibition of heme polymerization in Plasmodium falciparum after 15 min by liquid scintillation counting analysis in presence of [14C]-hemin chloride,Confirmatory,,
1785,1097036,1,2,,103401109,441074,Unspecified,,,,,Antiamoebic activity against Entamoeba histolytica,Other,,
1786,1125212,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as P-Q ECG interval at 15 mg/kg, ip after 30 mins (Rvb = 51.6 +/- 0.927 ms)",Other,24637077.0,
1787,1125213,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as P-Q ECG interval at 15 mg/kg, ip measured immediately at 0 min (Rvb = 52.4 +/- 0.927 ms)",Other,24637077.0,
1788,1125214,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as QRS ECG interval at 15 mg/kg, ip measured immediately at 0 min (Rvb = 19.6 +/- 1.142 ms)",Other,24637077.0,
1789,1125215,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as Q-T ECG interval at 15 mg/kg, ip measured immediately at 0 min (Rvb = 78.8 +/- 1.030 ms)",Other,24637077.0,
1790,1125216,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as P-Q ECG interval at 15 mg/kg, ip after 15 mins (Rvb = 52.2 +/- 1.158 ms)",Other,24637077.0,
1791,1125217,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as QRS ECG interval at 15 mg/kg, ip after 15 mins (Rvb = 18.9 +/- 1.563 ms)",Other,24637077.0,
1792,1125218,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as Q-T ECG interval at 15 mg/kg, ip after 15 mins (Rvb = 79.4 +/- 1.270 ms)",Other,24637077.0,
1793,1125219,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as QRS ECG interval at 15 mg/kg, ip after 30 mins (Rvb = 19.9 +/- 1.393 ms)",Other,24637077.0,
1794,1125220,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as Q-T ECG interval at 15 mg/kg, ip after 30 mins (Rvb = 78.3 +/- 0.860 ms)",Other,24637077.0,
1795,1125221,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as P-Q ECG interval at 15 mg/kg, ip after 45 mins (Rvb = 52.5 +/- 0.780 ms)",Other,24637077.0,
1796,1125222,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as QRS ECG interval at 15 mg/kg, ip after 45 mins (Rvb = 20.2 +/- 1.348 ms)",Other,24637077.0,
1797,1125223,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as Q-T ECG interval at 15 mg/kg, ip after 45 mins (Rvb = 78.8 +/- 0.927 ms)",Other,24637077.0,
1798,1125224,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as P-Q ECG interval at 15 mg/kg, ip after 60 mins (Rvb = 52.9 +/- 0.924 ms)",Other,24637077.0,
1799,1125225,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as QRS ECG interval at 15 mg/kg, ip after 60 mins (Rvb = 19.3 +/- 0.873 ms)",Other,24637077.0,
1800,1125226,1,1,,103401109,441074,Unspecified,,,,,"Toxicity in anaesthetized-Wistar rat assessed as Q-T ECG interval at 15 mg/kg, ip after 60 mins (Rvb = 79.7 +/- 0.965 ms)",Other,24637077.0,
1801,1125262,1,2,,103401109,441074,Unspecified,,,,,"Toxicity in anesthetized-normotensive Wistar rat assessed as heart rate at 15 mg/kg, ip measured immediately at 0 min (Rvb = 316.62 +/- 9.643 bpm)",Other,24637077.0,
1802,1125263,1,2,,103401109,441074,Unspecified,,,,,"Toxicity in anesthetized-normotensive Wistar rat assessed as heart rate at 15 mg/kg, ip after 15 mins (Rvb = 313.93 +/- 9.912 bpm)",Other,24637077.0,
1803,1125264,1,2,,103401109,441074,Unspecified,,,,,"Toxicity in anesthetized-normotensive Wistar rat assessed as heart rate at 15 mg/kg, ip after 30 mins (Rvb = 317.68 +/- 7.631 bpm)",Other,24637077.0,
1804,1125265,1,2,,103401109,441074,Unspecified,,,,,"Toxicity in anesthetized-normotensive Wistar rat assessed as heart rate at 15 mg/kg, ip after 45 mins (Rvb = 316.82 +/- 8.452 bpm)",Other,24637077.0,
1805,1125266,1,2,,103401109,441074,Unspecified,,,,,"Toxicity in anesthetized-normotensive Wistar rat assessed as heart rate at 15 mg/kg, ip after 60 mins (Rvb = 314.96 +/- 9.442 bpm)",Other,24637077.0,
1806,1125272,1,2,,103401109,441074,Unspecified,,,,,"Antiarrhythmic activity in barium chloride-induced Wistar rat assessed as increase in appearance time of arrhythmia at 15 mg/kg, ip administered 60 mins before barium chloride challenge (Rvb = 129.4 +/- 4.373 sec)",Other,24637077.0,
1807,1125274,1,2,,103401109,441074,Unspecified,,,,,"Antiarrhythmic activity in barium chloride-induced Wistar rat assessed as increase in mortality time at 15 mg/kg, ip administered 60 mins before barium chloride challenge (Rvb = 682.8 +/- 9.656 secs)",Other,24637077.0,
1808,1132565,1,2,,103401109,441074,Active,,,,,Antiarrhythmic activity in rabbit heart assessed as reduction in aconitine-induced ventricular arrhythmia at 40 mg/l after 30 mins by electrocardiographic analysis,Other,650662.0,
1809,1132566,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in iv dosed mongrel dog assessed as reduction in ouabain-induced ventricular arrhythmia by electrocardiographic analysis,Other,650662.0,
1810,1132567,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in iv dosed mongrel dog assessed as reduction in ouabain-induced ventricular arrhythmia measured as duration of action at MED by electrocardiographic analysis,Other,650662.0,
1811,1132568,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in mongrel dog Harris two-stage coronary ligation model assessed as reduction in ectopic beats by electrocardiographic analysis,Other,650662.0,
1812,1132569,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in mongrel dog Harris two-stage coronary ligation model assessed as reduction in ectopic beats measured as duration of action at MED by electrocardiographic analysis,Other,650662.0,
1813,1133877,1,2,,103401109,441074,Unspecified,,,,,"Antiarrhythmic activity in anesthetized acute myocardial infarction dog model assessed as normal ECG complexes at 2.5 mg/kg, iv administered 10 mins prior to infarction measured during 1-hr postinfarction period (Rvb = 19%)",Other,845875.0,
1814,1133878,1,2,,103401109,441074,Unspecified,,,,,"Antiarrhythmic activity in anesthetized acute myocardial infarction dog model assessed as normal ECG complexes at 10 mg/kg, iv administered 10 mins prior to infarction measured during 1-hr postinfarction period (Rvb = 19%)",Other,845875.0,
1815,1133879,1,2,,103401109,441074,Unspecified,,,,,"Antiarrhythmic activity in anesthetized acute myocardial infarction dog model assessed as normal ECG complexes at 5 mg/kg, iv administered 10 mins prior to infarction measured during 1-hr postinfarction period (Rvb = 19%)",Other,845875.0,
1816,1133890,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in iv dosed anesthetized acute myocardial infarction dog model assessed as protection against ventricular arrhythmia development administered 10 mins prior to infarction measured during 1-hr postinfarction period,Other,845875.0,
1817,1133891,1,1,,103401109,441074,Unspecified,,,,,"Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in PR interval at 2.5 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 0 ms)",Other,845875.0,
1818,1133892,1,1,,103401109,441074,Unspecified,,,,,"Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in PR interval at 5 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 0 ms)",Other,845875.0,
1819,1133893,1,1,,103401109,441074,Unspecified,,,,,"Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in PR interval at 10 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 0 ms)",Other,845875.0,
1820,1133900,1,1,,103401109,441074,Unspecified,,,,,"Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in QT duration at 2.5 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 2 ms)",Other,845875.0,
1821,1133901,1,1,,103401109,441074,Unspecified,,,,,"Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in QT duration at 5 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 2 ms)",Other,845875.0,
1822,1133902,1,1,,103401109,441074,Unspecified,,,,,"Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in QT duration at 10 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 2 ms)",Other,845875.0,
1823,1133909,1,2,,103401109,441074,Unspecified,,,,,"Reduction in heart rate in anesthetized acute myocardial infarction dog model at 2.5 mg/kg, iv administered 10 mins prior to infarction (Rvb = 6 bpm)",Other,845875.0,
1824,1133916,1,2,,103401109,441074,Unspecified,,,,,"Reduction in heart rate in anesthetized acute myocardial infarction dog model at 5 mg/kg, iv administered 10 mins prior to infarction (Rvb = 6 bpm)",Other,845875.0,
1825,1133917,1,2,,103401109,441074,Unspecified,,,,,"Reduction in heart rate in anesthetized acute myocardial infarction dog model at 10 mg/kg, iv administered 10 mins prior to infarction (Rvb = 6 bpm)",Other,845875.0,
1826,1145051,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as change in maximum driving rate at 61.6 uM/l after 5 mins,Other,1255662.0,
1827,1145052,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as change in maximum driving rate at 30.8 uM/l after 5 mins,Other,1255662.0,
1828,1145053,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as change in maximum driving rate at 15.4 uM/l after 5 mins,Other,1255662.0,
1829,1145065,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in ip dosed Swiss-Webster albino mouse assessed as prevention of chloroform-induced ventricular fibrillation,Other,1255662.0,
1830,1145066,1,1,,103401109,441074,Unspecified,,,,,Toxicity in ip dosed Swiss-Webster albino mouse,Other,1255662.0,
1831,1145067,1,2,,103401109,441074,Unspecified,,,,,"Therapeutic index, ratio of LD50 for toxicity to ED50 for antiarrhythmic activity in ip dosed Swiss-Webster albino mouse",Other,1255662.0,
1832,1145068,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as change in spontaneous rate at 61.6 uM/l after 5 mins,Other,1255662.0,
1833,1145069,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as change in spontaneous rate at 30.8 uM/l after 5 mins,Other,1255662.0,
1834,1145070,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as change in spontaneous rate at 15.4 uM/l after 5 mins,Other,1255662.0,
1835,1145122,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in Hartley guinea pig atria assessed as reversible decrease in maximum driving rate compound treated for 5 mins measured up to 2 hrs post washout,Other,1255662.0,
1836,1149685,1,2,,103401109,441074,Unspecified,,,,,Antiarrhythmic activity in po dosed Swiss-Webster mouse assessed as protection against chloroform-induced ventricular fibrillation administered in 4% acacia,Other,874956.0,
1837,1152142,1,3,,103401109,441074,Active,84028191.0,1565.0,0.017,IC50,Inhibition of recombinant CYP2D6 (unknown origin) using 7-methoxy-4-trifluoromethylcoumarin as substrate,Confirmatory,24793360.0,
1838,1159387,1,2,,103401109,441074,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
1839,1159389,1,2,,103401109,441074,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1840,1159390,1,2,,103401109,441074,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1841,1159391,1,2,,103401109,441074,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1842,1159395,1,2,,103401109,441074,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
1843,1159396,1,2,,103401109,441074,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
1844,1159524,1,1,,56320932,441074,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1845,1159580,2,1,,268734487,441074,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1846,1159585,1,2,,307068822,441074,Inactive,124801388.0,812762.0,,CDPK1_IC50_uM,Biochemical screen of P. falciparum CDPK1,Confirmatory,26934697.0,
1847,1159586,1,2,,307068822,441074,Inactive,124513486.0,813740.0,,PK6_IC50_uM,Biochemical screen of P. falciparum PK6,Confirmatory,26934697.0,
1848,1159587,1,2,,307068822,441074,Inactive,124801229.0,812721.0,,PK7_IC50_uM,Biochemical screen of P. falciparum PK7,Confirmatory,26934697.0,
1849,1159588,1,2,,307068822,441074,Inactive,124511890.0,2655116.0,,CDPK4_IC50_uM,Biochemical screen of P. falciparum CDPK4,Confirmatory,26934697.0,
1850,1159589,1,2,,307068822,441074,Inactive,124803797.0,810694.0,,,Biochemical screen of P. falciparum MAPK2,Other,26934697.0,
1851,1159606,1,1,,56320932,441074,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1852,1159607,2,1,,312309725,441074,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1853,1159620,1,1,,103401109,441074,Active,,,,,Summary of drug indications.,Other,,
1854,1164254,1,2,,103401109,441074,Active,84028191.0,1565.0,25.1,IC50,Inhibition of human recombinant CYP2D6 incubated for 5 mins by fluorescence assay,Confirmatory,25221656.0,
1855,1165282,1,2,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of human CYP2D6 at 10 uM,Other,25244572.0,
1856,1168290,1,2,,103401109,441074,Active,84028191.0,1565.0,0.12,IC50,Inhibition of CYP2D6 (unknown origin) using AMMC by fluorescence assay,Confirmatory,25300820.0,
1857,1181451,1,2,,103401109,441074,Active,84028191.0,1565.0,25.0,IC50,Inhibition of recombinant human CYP2D6 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Confirmatory,24974340.0,
1858,1181466,1,2,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of recombinant human CYP2D6 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Other,24974340.0,
1859,1186289,1,2,,103401109,441074,Active,84028191.0,1565.0,0.006,IC50,Inhibition of CYP2D6 in human liver microsome,Confirmatory,25082126.0,
1860,1195137,1,1,,103401109,441074,Unspecified,,,,,Permeability of the compound in DMSO/Prisma HT buffer at 1:200 ratio after 2 hrs by PAMPA-BBB assay,Other,25868744.0,
1861,1202799,1,2,,103401109,441074,Unspecified,7531135.0,3757.0,,,Inhibition of human ERG expressed in CHL cells assessed as tail current at 10 uM after 7 mins by patch clamp assay relative to control,Other,25654185.0,
1862,1204626,1,1,,103401109,441074,Unspecified,,,,,Apparent permeability of the compound at 50 uM after 5 hrs by PAMPA method,Other,25974856.0,
1863,1204627,1,1,,103401109,441074,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco2 cells by LC-MS analysis,Other,25974856.0,
1864,1207170,1,2,,103401109,441074,Active,215273881.0,6331.0,16.6,IC50,Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA,Confirmatory,21300721.0,
1865,1207199,1,2,,103401109,441074,Active,5921694.0,100135490.0,15.6,IC50,Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes,Confirmatory,21300721.0,
1866,1207229,1,1,,103401109,441074,Active,,,0.3,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
1867,1207260,1,2,,103401109,441074,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
1868,1207693,1,2,,103401109,441074,Active,5921694.0,100135490.0,15.6,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
1869,1207694,1,2,,103401109,441074,Active,308153651.0,775.0,19.82,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
1870,1207695,1,2,,103401109,441074,Active,116412.0,24239.0,10.0,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes,Confirmatory,22761000.0,
1871,1207764,1,1,,103401109,441074,Active,,,6.4,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
1872,1209336,1,2,,103401109,441074,Unspecified,,,,,"Ratio of drug level in brain to plasma in Sprague-Dawley rat at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1873,1209344,1,2,,103401109,441074,Unspecified,,,,,"Ratio of drug level in cerebrospinal fluid to unbound plasma concentration in Sprague-Dawley rat at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1874,1209352,1,1,,103401109,441074,Unspecified,,,,,"Ratio of unbound brain concentration to drug level in cerebrospinal fluid in Sprague-Dawley rat at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1875,1209360,1,1,,103401109,441074,Unspecified,,,,,"Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1876,1209380,1,2,,103401109,441074,Unspecified,,,,,"AUC(0 to 7 hrs) in Sprague-Dawley rat plasma at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1877,1209388,1,2,,103401109,441074,Unspecified,,,,,"AUC(0 to infinity) in Sprague-Dawley rat plasma at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1878,1209396,1,2,,103401109,441074,Unspecified,,,,,"AUC(0 to 7 hrs) in Sprague-Dawley rat cerebrospinal fluid at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1879,1209404,1,2,,103401109,441074,Unspecified,,,,,"AUC(0 to infinity) in Sprague-Dawley rat cerebrospinal fluid at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1880,1209412,1,2,,103401109,441074,Unspecified,,,,,"AUC(0 to 7 hrs) in Sprague-Dawley rat brain at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1881,1209420,1,2,,103401109,441074,Unspecified,,,,,"AUC(0 to infinity) in Sprague-Dawley rat brain at 35 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
1882,1209581,1,2,,103401109,441074,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1883,1209582,1,1,,103401109,441074,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1884,1209583,1,1,,103401109,441074,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1885,1209593,1,1,,103401109,441074,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1886,1211293,1,2,,103401109,441074,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
1887,1211294,1,1,,103401109,441074,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
1888,1211295,1,1,,103401109,441074,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
1889,1211296,1,2,,103401109,441074,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
1890,1211297,1,1,,103401109,441074,Unspecified,,,,,Drug recovery in plasma (unknown origin),Other,21098647.0,
1891,1211298,1,1,,103401109,441074,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21098647.0,
1892,1211791,1,1,,103401109,441074,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
1893,1211792,1,1,,103401109,441074,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
1894,1211793,1,1,,103401109,441074,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
1895,1211794,1,2,,103401109,441074,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
1896,1211795,1,1,,103401109,441074,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
1897,1211796,1,1,,103401109,441074,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1898,1211797,1,1,,103401109,441074,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1899,1211798,1,1,,103401109,441074,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
1900,1215347,1,2,,103401109,441074,Inactive,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis in presence of NADPH,Other,21393461.0,
1901,1215348,1,2,,103401109,441074,Inactive,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis,Other,21393461.0,
1902,1215349,1,2,,103401109,441074,Inactive,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 shift assay in presence of NADPH,Other,21393461.0,
1903,1215350,1,2,,103401109,441074,Inactive,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 shift assay,Other,21393461.0,
1904,1219167,1,2,,103401109,441074,Unspecified,146345508.0,6583.0,,,Inhibition of OCTN1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]ergothioneine substrate uptake at 1500 uM by liquid scintillation counting,Other,23073734.0,
1905,1219168,1,2,,103401109,441074,Unspecified,8928257.0,6584.0,,,Inhibition of OCTN2 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]carnitine substrate uptake at 1500 uM by liquid scintillation counting,Other,23073734.0,
1906,1222793,1,1,,103401109,441074,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
1907,1224863,1,1,,316919784,441074,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1908,1224865,1,2,,56320932,441074,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1909,1233552,1,1,,103401109,441074,Active,,,34.81,IC50,Cytotoxicity against human WI38 cells by MTT assay,Confirmatory,26063305.0,
1910,1233553,1,1,,103401109,441074,Active,,,25.99,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay,Confirmatory,26063305.0,
1911,1233554,1,1,,103401109,441074,Unspecified,,,,,"Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream forms",Other,26063305.0,
1912,1233559,1,1,,103401109,441074,Active,,,0.1944,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay,Confirmatory,26063305.0,
1913,1233560,1,1,,103401109,441074,Unspecified,,,,,"Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Plasmodium falciparum 3D7",Other,26063305.0,
1914,1238338,1,1,,103401109,441074,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6 (unknown origin) at 1 uM by luminescent readout-based method,Other,26096679.0,
1915,1244277,1,1,,103401109,441074,Active,84028191.0,1565.0,0.018000000000000002,IC50,Inhibition of CYP2D6 (unknown origin),Confirmatory,26204510.0,
1916,1254877,1,1,,103401109,441074,Active,84028191.0,1565.0,0.03,IC50,Inhibition of CYP2D6 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,Confirmatory,26355532.0,
1917,1257258,1,1,,103401109,441074,Unspecified,116412.0,24239.0,5.6,IC50,Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in rat ventricular myocytes,Confirmatory,,
1918,1259310,1,1,,104169976,441074,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1919,1259313,1,1,,56320932,441074,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1920,1259318,1,1,,56320932,441074,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1921,1259325,1,2,,336956231,441074,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1922,1259406,1,1,,363920470,441074,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
1923,1259406,1,1,1.0,363920470,441074,Inactive,26638650.0,3778.0,0.0317114,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
1924,1259406,1,1,2.0,363920470,441074,Inactive,4758626.0,3779.0,0.0227252,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1925,1259406,1,1,3.0,363920470,441074,Inactive,5031823.0,10242.0,-0.00383433,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
1926,1259406,1,1,4.0,363920470,441074,Inactive,26051275.0,27345.0,0.0523591,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
1927,1259406,1,1,5.0,363920470,441074,Inactive,160410009.0,389816.0,0.0176676,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1928,1259406,1,1,6.0,363920470,441074,Inactive,26638650.0,3778.0,0.00721845,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
1929,1259406,1,1,7.0,363920470,441074,Inactive,4758626.0,3779.0,0.08330189999999998,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1930,1259406,1,1,8.0,363920470,441074,Inactive,5031823.0,10242.0,0.0110542,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
1931,1259406,1,1,9.0,363920470,441074,Inactive,26051275.0,27345.0,0.073755,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
1932,1259406,1,1,10.0,363920470,441074,Inactive,5031823.0,10242.0,0.024391200000000002,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
1933,1259407,1,1,,363898622,441074,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1934,1259413,1,2,,104169976,441074,Active,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
1935,1259415,1,1,,56320932,441074,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
1936,1259416,1,2,,340081932,441074,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1937,1259416,1,2,,375174892,441074,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1938,1259421,1,1,,340081932,441074,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1939,1259421,1,1,,375174892,441074,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1940,1259423,1,2,,354818956,441074,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1941,1259423,1,2,,354918926,441074,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1942,1259423,1,2,,354920645,441074,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
